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ABSTRACT 
 
Clinical studies link vitamin D deficiency and musculoskeletal pain, both of which occur more frequently 
in women.  However, a causal relationship has been difficult to establish and it is not clear whether 
vitamin D metabolites directly influence nociceptors (‘pain-sensing’ neurons).  It was shown here, via 
immunohistochemistry and western blot, that rat putative nociceptors contain vitamin D receptors (VDRs) 
and metabolic enzymes, whose expression is regulated by ovarian hormones.  In ovariectomized rats a 
vitamin D deficient diet induces balance deficits and deep tissue mechanical hyperalgesia, concurrent 
with muscle hyperinnervation by presumed nociceptors.  Balance deficits, muscle mechanical 
hypersensitivity, and hyperinnervation are not corrected by elevated dietary calcium.  In primary sensory 
cultures, VDR is enriched in c-fiber growth cones and regulates neurite outgrowth through VDR rapid 
response pathways.  Therefore, vitamin D metabolites act directly on nociceptive neurons to inhibit 
axonal sprouting, accounting for hypovitaminosis D-induced muscle hyperinnervation, and possibly 
contributing to hypersensitivity.  
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General Background 
Accumulating evidence supports a role for vitamin D in certain types of pain.  For example, vitamin 
D deficiency is associated with chronic musculoskeletal pain and acroparaesthesia (numbness, burning, or 
tingling in the extremities) (Benson, Wilson et al. 2006; de Torrente de la Jara, Pecoud et al. 2006; Glerup 
and Eriksen 1999; Gloth, Lindsay et al. 1991; Heidari, Shirvani et al. 2010; Macfarlane, Palmer et al. 
2005; McBeth, Pye et al. 2010; Plotnikoff and Quigley 2003).  Up to 93% of patients who report chronic 
musculoskeletal pain are vitamin D deficient (Plotnikoff and Quigley 2003).  Several studies have shown 
that this pain may be relieved by vitamin D supplementation (de Torrente de la Jara, Pecoud et al. 2006; 
Glerup and Eriksen 1999; Gloth, Lindsay et al. 1991).  However, a direct causal relationship has not been 
established and potential mechanisms underlying this phenomenon have remained unexplored.  
 
Musculoskeletal pain 
Musculoskeletal pain in general has enormous socioeconomic impacts on our society.  It can 
significantly decrease the quality of life for an individual by preventing entry into the workforce and 
rendering many incapable of completing simple daily activities. The council for disability awareness 
estimates that in 2006, of the $79.9 billion in social security disability insurance payouts and $7.2 billion 
in long-term disability payouts from private companies, musculoskeletal disorders accounted for 25.7% of 
all disability claims making it the number one cause for long-term disability (Awareness 2006).  
Musculoskeletal pain also substantially affects the load on our health care system.  It is estimated that the 
prevalence of chronic musculoskeletal pain (pain lasting longer than 3 months)  in adolescents is between 
27.5-36% (De Inocencio 2004) and 35-50% in adults (Bergman 2007). In 10-22% of adults this pain is 
widespread (Abusdal, Hagen et al. 1997; Bergman, Herrstrom et al. 2001; Croft, Rigby et al. 1993; Hunt, 
Silman et al. 1999; Schochat and Raspe 2003; White, Speechley et al. 1999; Wolfe, Ross et al. 1995).  In 
addition, 20-40% of all primary health care visits are due to musculoskeletal complaints (Andersson, 
Ejlertsson et al. 1999; De Inocencio 2004).  Despite these statistics the mechanisms and pathology that 
lead to chronic musculoskeletal pain are poorly understood. 
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Vitamin D 
The secosteroid vitamin D is generally considered a prosteroid hormone and is not technically a 
vitamin because humans can synthesize it; however, most individuals also acquire vitamin D from natural 
dietary sources (i.e. fatty fish), fortified foods, or nutritional supplements (Yetley 2008).   Synthesis 
begins upon exposure to UVB light, when 7-dehydroxycholesterol is converted to previtamin D within 
the keratinocyte cell membrane of the skin (Holick 2005).  Previtamin D spontaneously isomerizes into 
vitamin D during the course of several hours and enters the blood stream through mass action, due to the 
presence of vitamin D binding proteins within the blood (Holick 2005).  Whether synthesized or from 
nutritional sources, vitamin D is converted in the liver to the main circulating form, 25-hydroxyvitamin D 
(25(OH)D) (Horst, Reinhardt et al. 2005).  25(OH)D can be further transformed by 25-hydroxyvitamin D 
1α-hydroxylase/cytochrome P450, family 27, subfamily B, polypeptide 1 (CYP27B1) into 1,25-
dihydroxyvitamin D (1,25(OH)2D), which is the most well understood active metabolite (Horst, Reinhardt 
et al. 2005).  Conversion of 25(OH)D into 1,25(OH)2D occurs largely in kidney, but other cell types 
express CYP27B1 and can locally convert circulating precursor to active hormone (Jones 2007).  
Hydroxylation of 1,25(OH)2D to form 1,24,25-trihydroxyvitamin D by the widely expressed enzyme, 25-
hydroxyvitamin D 24-hydroxylase/cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24), is 
an initial step in the pathway of 1,25(OH)2D degradation, but CYP24 also produces other vitamin D 
metabolites (i.e. 24,25-dihydroxyvitamin D), whose actions are just beginning to be understood (Omdahl, 
Bobrovnikova et al. 2003; Sakaki, Kagawa et al. 2005).  CYP27B1 and CYP24 therefore act as opposing 
forces in regulating the concentration of 1,25(OH)2D.  This active hormone binds to vitamin D receptors 
(VDRs), which are spatially dynamic and may be localized within the nucleus where they influence gene 
transcription, or within the cytoplasm and membrane where they modulate ion flux and the generation of 
second messengers (Mizwicki and Norman 2009).   
 Vitamin D deficiency is prevalent worldwide.  It is thought that the best predictor of vitamin D 
status is serum 25(OH)D levels, because 1,25(OH)2D has a relatively short half life and is more tightly 
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regulated (Jones 2008).  The NIH recently revised its standards for serum 25(OH)D levels according to a 
recent Institute of Medicine committee.  Previously anything >37.5nmol/L was considered sufficient, 
<37.5nmol was insufficient, and below 25nmol/L was deficient.  Now >50nmol/L (20ng/ml) is 
considered sufficient for 97.5% of the population, and < 30nmol/L (12ng/ml) is considered deficient 
(Institute of Medicine 2010).  However, a number of researchers feel that these levels should be adjusted 
even higher (Dawson-Hughes, Heaney et al. 2005; Hollis 2005).  Peak calcium absorption from the 
intestines occurs when serum 25(OH)D is approximately 80pmol/L (32ng/ml) (Heaney, Dowell et al. 
2003) and  levels >80pmol/L  may be required to alleviate secondary hyperparathyroidism in the elderly 
(Vieth, Ladak et al. 2003), so some have suggested that above 80nmol/L (32ng/ml) should be considered 
replete and below this level should be considered insufficient.  Some researchers believe that serum 
25(OH)D concentrations below 50nmol/L (20ng/ml) should be considered deficient, because there is a 5-
15% increase in parathyroid hormone and higher bone turnover (Chapuy, Preziosi et al. 1997; Holick 
2009; Need 2006).  When concentrations fall below 25nmol/L (10ng/ml) there is an increased fracture 
risk (Cummings, Black et al. 1993; Ooms, Roos et al. 1995) and below 12.5nmol/L (5ng/ml) is when 
overt osteomalacia or rickets becomes apparent (Need 2006).  While the data available concerning the 
upper levels are not clear, serum levels above 125nmol/L (50ng/ml) may begin to raise concerns (Institute 
of Medicine 2010), however toxicity rarely occurs below 500nmol/L (Heaney 2008).  Based on the 
National Health and Nutrition Examination Survey (NHANES), approximately 70% of the population has 
serum 25(OH)D concentrations that are less than 80nmol/L (32ng/ml), 30% has levels less than 50nmol/L 
(20ng/ml), and 5% has levels less than 27.5nmol/L (11ng/ml) (Yetley 2008).    
 
Vitamin D and musculoskeletal pain 
A significant proportion of patients who report chronic musculoskeletal pain are vitamin D deficient, 
with serum 25(OH)D concentrations that are less than 50nmol/L (20ng/ml) (Benson, Wilson et al. 2006; 
Macfarlane, Palmer et al. 2005; Plotnikoff and Quigley 2003).  Depending on the population studied and 
the cut-off values of 25(OH)D used to determine deficiency, the reported percentage of patients with 
5 
 
musculoskeletal pain that are vitamin D deficient varies from 25-100%.  Gloth et al. first described five 
patients with severe pain triggered by minimal movement or touch.  All five patients had 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) levels below 45pmol/L (normal range 50-190pmol/L) and four of 
the five patients had serum 25(OH)D levels below 50nmol/L (20ng/ml).  All patients recovered after 
vitamin D supplementation (Gloth, Lindsay et al. 1991).  A study of Australian Aborigenes showed that 
while 100% of Aborigenes with muscle pain had a levels of 25(OH)D below 50nmol/L (20ng/ml), only 
12.5% of Aborigines without muscle pain were vitamin D deficient (Benson, Wilson et al. 2006).   Of 150 
people who reported to a US community clinic with non-specific musculoskeletal pain, 93% had 
25(OH)D levels below 50nmol/L (20ng/ml) (Plotnikoff and Quigley 2003).  A study in Norway of 276 
patients with musculoskeletal pain and 229 controls found that 81.6% of patients with leg pain and 60% 
with chronic widespread pain were vitamin D deficient (<20ng/ml) compared to only 36.1% of controls.  
They also show that average serum 25(OH)D levels were significantly lower in patients with leg pain 
(14.5ng/ml) or widespread pain (20.6ng/ml) than in control patients (33.1ng/ml) (Heidari, Shirvani et al. 
2010).  Results from a recent  European Male Ageing Study analyzing 3075 men age 49-79, found that 
25.5% of men with chronic widespread pain had 25(OH)D levels below 37.5nmol/L (15ng/ml), compared 
to only 18.6% in men with no pain (McBeth, Pye et al. 2010). Conversely a study in Switzerland of 
asylum seekers with hypovitaminosis D  (<21nmol/L) found that up to 91% experienced somatic pain, 
and 85% reported complete or partial resolution of symptoms after vitamin D treatment (de Torrente de la 
Jara, Pecoud et al. 2006).  In addition to pain, it has also been reported that 59% of Arab women with 
hypovitaminosis D experience acroparaesthesia. After vitamin D supplementation, 92% displayed 
improvement and 81% reported a complete remission of symptoms (Glerup and Eriksen 1999).  In 
addition to the growing number of studies linking vitamin D deficiency to musculoskeletal pain, there 
have also been several conflicting reports, which appear to stem from a focus on vitamin D deficiency and 
fibromyalgia (Block 2004; de Rezende Pena, Grillo et al. 2010; Tandeter, Grynbaum et al. 2009; Warner 
and Arnspiger 2008).  However, this issue may have been cleared up by Heidari et. al, who recently 
showed that while low vitamin D levels are linked to chronic widespread pain in general, vitamin D status 
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is not associated with chronic widespread pain subtype, fibromyalgia (Heidari, Shirvani et al. 2010).   All 
in all there is a significant clinical link between vitamin D deficiencies and non-specific musculoskeletal 
pain, but an understanding of how vitamin D affects the pain pathways of the nervous system is severely 
lacking.  
 
Vitamin D and the nervous system 
Vitamin D is becoming recognized as an important hormone in nervous system health.  VDR is 
expressed by neurons, oligodendrocytes, and astrocytes within the limbic system, basal ganglia, spinal 
cord, cerebellum, and cerebral cortex (Baas, Prufer et al. 2000; Eyles, Smith et al. 2005; Glaser, Veenstra 
et al. 1999; Neveu, Naveilhan et al. 1994; Perez-Fernandez, Alonso et al. 1997; Prufer, Veenstra et al. 
1999; Walbert, Jirikowski et al. 2001).  Studies have also shown that neurons and glia in the brain express 
CYP27B1 (Eyles, Smith et al. 2005; Zehnder, Bland et al. 2001), and CYP24 mRNA has been detected in 
glioma and primary glial cell culture (Naveilhan, Neveu et al. 1993), suggesting that the brain can 
regulate local 1,25(OH)2D concentrations.  Vitamin D signaling has been linked to cell survival, 
proliferation, and differentiation, and may be especially important during brain development (Eyles, 
Brown et al. 2003; Levenson and Figueiroa 2008).  In the adult, vitamin D supplementation has been 
proposed to improve outcomes in multiple sclerosis, Parkinson’s disease, and traumatic brain injury 
(Cekic, Sayeed et al. 2009; Myhr 2009; Newmark and Newmark 2007).  Expression of VDR has also 
been identified in fetal (E12-E21) DRG sensory neurons (Johnson, Grande et al. 1996; Veenstra, Prufer et 
al. 1998), but it was not established whether expression continues post-natally. Thus, accumulating 
evidence suggests that vitamin D signaling plays important roles in the nervous system. However, little is 
known about how vitamin D may affect pain pathways. 
 
Sex differences in musculoskeletal pain and vitamin D deficiency 
In all age groups after the age of five, vitamin D deficiency is more prevalent in women than men 
(Yetley 2008) .  Women are also twice as likely to develop chronic widespread pain (Bergman 2007). 
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This has led us to consider a role for ovarian hormones in the regulation of the vitamin D system and the 
development of pain.  While testosterone levels do not appear to affect serum 25(OH)D levels or VDR 
expression (Tiwari, Gupta et al. 2002), VDR expression is up-regulated by 17β-estradiol in some cell 
types,  including osteoblasts (Duque, El Abdaimi et al. 2002; Liel, Kraus et al. 1992; Mahonen and 
Maenpaa 1994), breast cancer cells (Escaleira, Sonohara et al. 1993; Gilad, Bresler et al. 2005), 
colonocytes and duodenocytes (Gilad, Bresler et al. 2005; Liel, Shany et al. 1999; Schwartz, Smirnoff et 
al. 2000), liver (Duncan, Glass et al. 1991), and uterus (Levy, Zuili et al. 1984; Walters 1981).  Gilad et. 
al. showed that the enhanced expression of VDR by 17β-estradiol is not through classical estrogen 
response elements, but through 1,25(OH)2D binding to membrane-localized estrogen receptors that 
rapidly activate transcription of VDR through a Ras-Raf-MEK-ERK-cJUN pathway (Gilad, Bresler et al. 
2005).  However, not all cell types respond the same, as 17β-estradiol inhibits VDR expression in the 
kidney (Duncan, Glass et al. 1991).  Estrogens can also increase 1,25(OH)2D concentrations locally by 
increasing CYP27B1 and decreasing CYP24 levels (Lechner, Bajna et al. 2006).  In fact, in women 
shortly after the estrogen surge of the menstrual cycle, 1,25(OH)2D serum levels are reportedly double 
what they are on day one of the menstrual cycle (Gray, McAdoo et al. 1982).  In addition, progesterone 
has been reported to enhance estrogen-induced CYP27B1 expression (Tanaka, Castillo et al. 1978).  Thus 
it appears that in general, vitamin D signaling is up-regulated by ovarian hormones.  This is interesting 
because musculoskeletal pain is primarily associated with low estrogen status.  For instance, a major side-
effect of aromatase inhibitors, which prevent the production of estrogens, is musculoskeletal pain (Felson 
and Cummings 2005; Garreau, Delamelena et al. 2006; Morales, Pans et al. 2006; Mouridsen 2006).  In 
addition, Leuprolide, a gonadotropin-releasing hormone agonist, which causes hypoestrogenemia, induces 
musculoskeletal pain in 25% of women who use it (Felson and Cummings 2005; Friedman, Juneau-
Norcross et al. 1993).  Furthermore, the prevalence for chronic widespread pain peaks in the 50’s and 
60’s, corresponding with the age of menopause onset, a time when hormone levels are naturally dropping.  
In fact, it is well known that generalized musculoskeletal pain is a symptom of menopause (Dugan, 
Powell et al. 2006; Greendale, Reboussin et al. 1998).  Asian women, who tend to have particularly low 
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estrogen levels during menopause (Cauley, Gutai et al. 1989; Randolph, Sowers et al. 2004) and are 
especially susceptible to vitamin D deficiency (Ford, Graham et al. 2006; Pal, Marshall et al. 2003; Shaw 
and Pal 2002), appear to be more susceptible to menopausal musculoskeletal pain, with one study 
reporting it as their most common menopausal symptom (Ho, Chan et al. 1999).  Hormone replacement 
therapy, which is known to increase serum 1,25(OH)2D3 levels (van Hoof, van der Mooren et al. 1994; 
van Hoof, van der Mooren et al. 1999), has been shown to relieve and prevent the generalized pain 
associated with menopause (Dugan, Powell et al. 2006).  In this study we examine whether the loss of 
ovarian hormones causes specific changes in the expression of vitamin D-related proteins in neurons that 
are part of the pain pathway. 
 
The Need for an Animal Model  
While clinical links between chronic musculoskeltal pain and vitamin D deficiency exist, 
confounding factors in humans make vitamin D deficiency difficult to analyze in isolation. Factors that 
contribute to a vitamin D deficiency, such as sex, skin color, smoking, body weight, socioeconomic 
status, age, and physical activity are also associated with musculoskeletal pain (Table 1). These factors 
may enhance susceptibility to vitamin D deficiency, which in turn cause musculoskeletal pain. 
Alternatively, vitamin D deficiency may be more likely to occur in individuals already susceptible to 
chronic musculoskeletal pain. An animal model of hypovitaminosis D-induced musculoskeletal pain will 
allow analysis without confounding factors. The studies described here will use a rat model, because rats 
are extensively used to study pain-related behavior and have been used to assess features of vitamin D 
deficiency for nearly 90 years (McCollum, Simmonds et al. 1922).  Female rats will be used, because of 
the high prevalence of vitamin D deficiency and musculoskeletal pain in women (Andersson, Ejlertsson et 
al. 1993; Bergman, Herrstrom et al. 2001; Bolland, Grey et al. 2007; Dawson-Hughes, Harris et al. 1997; 
Rollman and Lautenbacher 2001).  
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Pain Associated with Hyperinnervation of Tissue  
Increased peripheral nerve density is associated with several painful conditions (Di Sebastiano, Fink 
et al. 1995; Di Sebastiano, Fink et al. 1997; Fink, Di Sebastiano et al. 1994; Pang, Marchand et al. 1995; 
Reinert, Kaske et al. 1998; Reynolds and Fitzgerald 1995; Schubert, Weidler et al. 2005; Shinoda, Honda 
et al. 2003), and is known to occur in muscles, joints, and tendons (Reinert, Kaske et al. 1998; Schubert, 
Weidler et al. 2005; Shinoda, Honda et al. 2003).  Steroid hormones other than vitamin D are known to 
regulate axonal sprouting, leading us to speculate whether vitamin D metabolites also had this potential 
(Blacklock, Johnson et al. 2005). Preliminary data were obtained, revealing that muscles from rachitic rats 
(a severe vitamin D deficiency model) had increased levels of the c-fiber specific intermediate filament 
protein, peripherin, suggesting that the muscles from vitamin D deficient might be hyperinnervated 
(Figure 1). Therefore, the focus of these studies was on how a vitamin D deficiency affects nociceptors, 
the first order neurons of the pain and temperature pathway, whose distal axons innervate peripheral 
tissue. In the first study described here, putative nociceptors were examined to determine whether they 
contain the machinery needed to metabolize and directly respond to vitamin D metabolites.  It the second 
study, vitamin D status in rats was altered in order to determine whether a vitamin D deficiency can result 
in deep tissue hypersensitivity and muscle hyperinnervation. 
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TABLE 
 
 
 
 
Table 1. Factors that contribute to both musculoskeletal pain and vitamin D deficiency. 
 Vitamin D levels Musculoskeletal Pain 
Sex 
Vitamin D deficiency is more prevalent in 
women (Bolland, Grey et al. 2007; 
Dawson-Hughes, Harris et al. 1997).  
Chronic widespread pain is more 
prevalent in women (Andersson, 
Ejlertsson et al. 1993; Bergman, 
Herrstrom et al. 2001; Rollman and 
Lautenbacher 2001). 
Skin color 
Due to the competition of melanin for 
UVB rays, synthesis of vitamin D in the 
skin is less efficient as skin pigmentation 
increases (Armas, Dowell et al. 2007; 
Clemens, Adams et al. 1982). 
Chronic widespread pain prevalence is 
increased in African American women 
compared to Caucasian women (Gansky 
and Plesh 2007). In addition, black 
chronic pain patients experience a higher 
severity of pain (Edwards, Doleys et al. 
2001; McCracken, Matthews et al. 2001).  
Smoking 
Smokers have a higher prevalence of 
vitamin D deficiency (Sowers, Wallace et 
al. 1986) 
Smokers have a higher prevalence of 
musculoskeletal pain (Andersson, 
Ejlertsson et al. 1998; Brage and 
Bjerkedal 1996; Palmer, Syddall et al. 
2003; Yunus, Arslan et al. 2002).  
Body 
Weight 
There is a negative correlation of vitamin 
D levels and body mass index (Arunabh, 
Pollack et al. 2003; Bischof, Heinze et al. 
2006; Bolland, Grey et al. 2007; Need, 
Morris et al. 1993; Wortsman, Matsuoka 
et al. 2000).  
There is a positive correlation between 
body mass index and musculoskeletal pain 
(Salaffi, De Angelis et al. 2005; Sievert 
and Goode-Null 2005; Yunus, Arslan et 
al. 2002).  
Physical 
Activity 
Exercise improves vitamin D activity 
(Bell, Godsen et al. 1988; Klausen, Breum 
et al. 1993; Nelson, Meredith et al. 1988).  
Exercise alleviates chronic widespread 
pain (Jones, Adams et al. 2006; Linton 
and van Tulder 2001) 
Age 
Serum 25(OH)D  levels decrease with age 
(Holick, Matsuoka et al. 1989; Need, 
Morris et al. 1993; Sowers, Wallace et al. 
1986).  
The prevalence of musculoskeletal pain 
increases with age, peaking between the 
ages of 55-65 and then decreasing slightly 
thereafter (Andersson, Ejlertsson et al. 
1993; Croft, Rigby et al. 1993; Hunt, 
Silman et al. 1999; White, Speechley et al. 
1999; Wolfe, Ross et al. 1995).  
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FIGURE 
Figure 1. 
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Figure 1.  Increased peripherin content in muscles from vitamin D deficient rats. Western blots of lysates 
prepared from the lateral gastrocnemius muscles of control or rachitic vitamin D deficient rats. β actin 
was used to normalize intensity values, which are expressed in graphical form as fold change compared to 
control. 
  
13 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2. VITAMIN D RECEPTOR AND ENZYME EXPRESSION IN DORSAL ROOT 
GANGLIA OF ADULT FEMALE RATS: MODULATION BY OVARIAN HORMONES 
 
  
14 
 
ABSTRACT 
 
Vitamin D insufficiency impacts sensory processes including pain and proprioception, but little is known 
regarding vitamin D signaling in adult sensory neurons.  We analyzed female rat dorsal root ganglia 
(DRG) for vitamin receptor (VDR) and the vitamin D metabolizing enzymes CYP27B1 and CYP24.  
Western blots and immunofluorescence revealed the presence of these proteins in sensory neurons.  
Nuclear VDR immunoreactivity was present within nearly all neurons, while cytoplasmic VDR was 
found preferentially in unmyelinated calcitonin gene-related peptide (CGRP)-positive neurons, 
colocalizing with CYP27B1 and CYP24.  These data suggest that 1,25(OH)2D may affect sensory 
neurons through nuclear or extranuclear signaling pathways. In addition, local vitamin D metabolite 
concentrations in unmyelinated sensory neurons may be controlled through expression of CYP27B1 and 
CYP24.  Because vitamin D deficiency appears to exacerbate some peri-menopausal pain syndromes, we 
assessed the effect of ovariectomy on vitamin D-related proteins.  Two weeks following ovariectomy, 
total VDR expression in DRG dropped significantly, owing to a slight decrease in the percentage of total 
neurons expressing nuclear VDR and a large drop in unmyelinated CGRP-positive neurons expressing 
cytoplasmic VDR.  Total CYP27B1 expression dropped significantly, predominantly due to decreased 
expression within unmyelinated CGRP-positive neurons.  CYP24 expression remained unchanged.  
Therefore, unmyelinated CGRP-positive neurons appear to have a distinct vitamin D phenotype with 
hormonally-regulated ligand and receptor levels.  These findings imply that vitamin D signaling may play 
a specialized role in a neural cell population that is primarily nociceptive. 
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INTRODUCTION 
 
Vitamin D metabolites have widespread roles in human health.  In addition to well known actions on 
calcium homeostasis and bone remodeling, vitamin D has been linked to immunity, cardiovascular 
disease, and cancer (Holick and Chen 2008).  Accumulating evidence supports a role for vitamin D in 
certain types of pain.  For example, vitamin D deficiency is associated with chronic musculoskeletal pain 
and acroparaesthesia (numbness, burning, or tingling in the extremities) (Glerup and Eriksen 1999; Gloth, 
Lindsay et al. 1991; Masood, Narang et al. 1989; Plotnikoff and Quigley 2003).  Over 85% of patients 
who report chronic musculoskeletal pain have levels of serum 25-hydroxyvitamin D3 (25OHD3) that are 
less than 20ng/ml (50nmol/L) (Benson, Wilson et al. 2006; Macfarlane, Palmer et al. 2005; Plotnikoff and 
Quigley 2003), which is relieved by vitamin D supplementation (de Torrente de la Jara, Pecoud et al. 
2006; Glerup and Eriksen 1999; Gloth, Lindsay et al. 1991).  However, the mechanism by which vitamin 
D deficiency leads to altered sensation is unknown.  
Vitamin D is derived from diet or exposure to sunlight, converted in the liver to the main circulating 
form, 25-hydroxyvitamin D (25OHD), which is further transformed by 25-hydroxyvitamin D 1α-
hydroxylase/cytochrome P450, family 27, subfamily B, polypeptide 1 (CYP27B1) into  1,25-
dihydroxyvitamin D (1,25(OH)2D), which is the most well understood active metabolite.  Conversion of 
25(OH)D into 1,25(OH)2D occurs largely in kidney, but other cell types express CYP27B1 and can 
locally convert circulating precursor to active hormone (Jones 2007).  1,25(OH)2D binds to vitamin D 
receptors (VDRs), which are spatially dynamic and may be localized within the nucleus where they 
influence gene transcription, or within the cytoplasm and membrane where they modulate ion flux and the 
generation of second messengers (Mizwicki and Norman 2009).  Hydroxylation of 1,25(OH)2D to form 
1,24,25-trihydroxyvitamin D by the widely expressed enzyme, 25-hydroxyvitamin D 24-
hydroxylase/cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24), is an initial step in the 
pathway of 1,25(OH)2D degradation, but CYP24 also produces other vitamin D metabolites, whose 
actions are just beginning to be understood (Omdahl, Bobrovnikova et al. 2003; Sakaki, Kagawa et al. 
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2005).  The extent to which these vitamin D-related proteins are present within adult sensory neurons is 
unknown.  
 A number of factors can influence VDR signaling, including ovarian hormones.  For instance, VDR 
expression is generally up-regulated by 17β-estradiol (Gilad, Bresler et al. 2005). Further, estrogens can 
increase 1,25(OH)2D concentrations locally by increasing CYP27B1 and decreasing CYP24 levels 
(Lechner, Bajna et al. 2006).  In addition, progesterone has been reported to enhance estrogen-induced 
CYP27B1 expression (Tanaka, Castillo et al. 1978).  While it is not known whether ovarian hormones 
and vitamin D signaling mechanisms interact in sensory nerve pathways, peripheral sensory neurons do 
express estrogen and progesterone receptors (Chan, Rodriguez-Waitkus et al. 2000; Sohrabji, Miranda et 
al. 1994), and anecdotal evidence suggests that vitamin D and ovarian hormones may interact to influence 
pain sensation. For example, musculoskeletal pain is more prevalent in females and frequently 
exacerbated by menopause or pharmacological estrogen suppression (Andersson, Ejlertsson et al. 1993; 
Bergman, Herrstrom et al. 2001; Croft, Rigby et al. 1993; Dugan, Powell et al. 2006; Felson and 
Cummings 2005; Friedman, Juneau-Norcross et al. 1993; Garreau, Delamelena et al. 2006; Greendale, 
Reboussin et al. 1998; Morales, Pans et al. 2006; Mouridsen 2006; White, Speechley et al. 1999; Wolfe, 
Ross et al. 1995). Moreover, musculoskeletal pain induced by hypoestrogenemia is inversely correlated 
with serum 25(OH)D levels and can be partially ameliorated by high-dose vitamin D3 therapy (Khan, 
Reddy et al. 2009; Waltman, Ott et al. 2009).  To assess the potential for vitamin D signaling in peripheral 
sensory neurons and the possible influence of reproductive hormones, we examined expression patterns of 
VDR, CYP27B1, and CYP24 in adult dorsal root ganglia (DRG) in intact and ovariectomized female rats.   
 
MATERIALS AND METHODS 
 
Experimental preparations  
Five female Sprague Dawley (Harlan Laboratories, Indianapolis, IN) rats at six weeks of age 
were ovariectomized by bilateral hind flank incision following anesthesia with 60mg/kg ketamine (Pfizer, 
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New York, New York), 0.4mg/kg atropine (Baxter, Deerfield, IL), 8mg/kg xylazine (Lloyd Laboratories, 
Shenandoah, Iowa).  Four age-matched female rats were allowed to cycle normally and estrous cycle 
stage was tracked daily by vaginal lavage with an eyedropper and 0.9% saline (Becker, Arnold et al. 
2005).  After two weeks, all rats were euthanized by i.p. injection of sodium pentobarbital (150mg/kg, 
Ovation) followed by decapitation; cycling rats cycled normally during this two week period and were 
euthanized at estrus, as determined by an opaque vaginal smear consisting predominantly of cornified 
epithelial cells.  All rats were exposed to a 14hr light/ 10hr dark cycle and sacrificed 4-6 hr into the light 
cycle. All procedures were reviewed by the University of Kansas Medical Center Institutional Animal 
Care and Use Committee and conformed to all local and federal guidelines. 
DRGs from C3-S1 were removed and all left ganglia from each animal were pooled and stored in 
RNAlater (Ambion, Austin, Texas) at -20°C for western blot protein analysis.  The right DRGs were 
embedded in tissue chilled freezing medium (Electron Microscopy Sciences, Hatfield, PA), snap frozen, 
and stored at -80°C for immunofluorescence studies.  
 
Antibody Characterization 
In preliminary experiments several anti-VDR antibodies were tested by immunohistochemistry on 
rat DRG sections.  Antibodies GTX73019 (GeneTex, Irvine, CA), and Santa Cruz antibodies C-20, H81, 
and D-6 (Santa Cruz Biotechnology Inc., Santa Cruz, CA) all had very similar staining patterns, we chose 
to use the C-20 antibody, because a blocking peptide was available to confirm specificity.  The rabbit 
anti-VDR antibody C-20 was raised against a region within the last 50 amino acids on the C-terminal end 
of the rat VDR protein.   The antibody recognized a band of the expected size (50-55kDa) as well as 
several bands that have previously been shown with this antibody and other VDR antibodies(Gonzalez 
Pardo, Boland et al. 2008; Nangia, Butcher et al. 1998; Wang, Becklund et al. 2010).  The sheep anti-
CYP27B1 (The Binding Site, Birmingham, UK) was raised against a murine CYP27B1 peptide 
(RHVELREGEAAMRNQGKPEEDMPS) and recognized two bands, corresponding to sizes expected for 
full length CYP27B1 (56kDa) and a known splice variant that has no enzymatic activity (25kDa) (Diesel, 
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Radermacher et al. 2005).  The goat anti-CYP24 G-15 antibody (Santa Cruz Biotechnology Inc., Santa 
Cruz, Ca) was raised against 15 amino acids between amino acids 400-450 of the human CYP24a protein 
and recognized a single band corresponding to the expected size (55kDa).  All western blot bands and 
immunofluorescent staining with the above antibodies was almost completely abolished after overnight 
preincubation of the primary antibodies with the following blocking peptides (1:5 antibody:blocking 
peptide): VDR C-20 (Santa Cruz Biotechnology Inc., Santa Cruz, Ca), CYP27B1 G-20 (Santa Cruz 
Biotechnology Inc., Santa Cruz, Ca), CYP27B1 G-15 (Santa Cruz Biotechnology Inc., Santa Cruz, Ca).  
 Peripherin selectively identifies unmyelinated neurons (Goldstein, House et al. 1991).  Because of 
potential interactions with double staining, two different peripherin antibodies were used.  Chicken IgY 
anti-peripherin AB9282 (Millipore, Billerica, MA) was raised against recombinant peripherin protein and 
rabbit anti-peripherin AB1530 (Millipore, Billerica, MA) was raised against a trp-E fusion protein 
containing all but the four N-terminal amino acids. The rabbit anti-peripherin antibody has been 
previously characterized (Tseng, Chau et al. 2008), and the percentage of DRG neurons expressing 
peripherin was similar to other accounts (Table 1) (Goldstein, House et al. 1991).  Double staining of 
DRG with both the chicken and rabbit antibodies revealed identical staining patterns. 
Calcitonin gene-related peptide (CGRP) resides within NGF-dependent sensory neurons (Lawson 
1992), and again two separate antibodies were used.  Goat anti-CGRP P01256 (AbD Serotec, Raleigh, 
NC) was raised against synthetic rat CGRP conjugated to gamma globulin, and sheep anti-CGRP CA1137 
(Enzo Life Sciences, Plymouth Meeting, PA) was raised against synthetic rat CGRP conjugated to bovine 
serum albumin.  These two antibodies had identical staining patterns, which have been previously 
characterized (Ruscheweyh, Forsthuber et al. 2007; Yasuhara, Aimi et al. 2008), and the percentage of 
DRG neurons expressing CGRP was similar to that reported by others (Table 1) (Lawson 1992).  
 
Western Blots 
Pooled left DRGs were homogenized in 350μl of RP1 buffer (Machery-Nagel, Düren, Germany) 
with 3.5μl of β-mercaptoethanol (Sigma-Aldrich Corp, St. Louis, MO) and proteins extracted using a 
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Protein/RNA Nucleospin kit (Machery-Nagel, Düren, Germany).   Proteins were separated side by side on 
4-12% Bis-Tris precast gels (Invitrogen, Carlsbad, Ca) and transferred to PVDF membrane (Bio-Rad, 
Hercules, CA).  Membranes were blocked with 5% nonfat milk, 0.1% bovine serum albumin, and 2% 
normal serum from the secondary antibody host.  Blots were probed overnight at 4°C using anti-VDR C-
20 (1:50 rabbit IgG, Santa Cruz), anti-CYP27B1 (1:50 sheep IgG, The Binding Site), or anti-CYP24 G-15 
(1:50 goat IgG, Santa Cruz).   Secondary antibodies conjugated to alkaline phosphatase or horseradish 
peroxidase were added for 2hr at room temperature. Blots were developed with either Biorad Immuno-
Star AP substrate (Bio-Rad, Hercules, CA) or Thermo Scientific SuperSignal Chemiluminescent substrate 
(Rockford, IL).  Blots were stripped (Restore Western Blot Stripping Buffer, Thermo Scientific, 
Rockford, IL) and reprobed with 1:2000 mouse anti-GAPDH (Millipore, Billerica, MA).  Images were 
acquired on a Molecular Imager ChemiDoc XRS system (Bio-Rad, Hercules, CA)and analyzed with 
Quantity One software (Bio-Rad, Hercules, CA).  Adjusted volumes (Intensity*mm2) of bands of interest 
were normalized to GAPDH in the same lane, and values for animal replicates averaged. Significance 
(p<0.05) was determined by student’s t-test. The images presented here have been cropped to show 
representative lanes/bands and adjusted for brightness and contrast.  
 
Immunofluorescence  
DRGs from each animal were sectioned at a thickness of 10μm and stored at -80oC. Thawed 
sections were post-fixed 30 min in 4% formaldehyde freshly-prepared from paraformaldehyde (Sigma-
Aldrich, St. Louis, MO) in phosphate buffered saline (PBS).  Slides were incubated 20 min in blocker 
containing 30% normal serum (Equitech-Bio Inc., Kerrville, TX) from the secondary antibody host, 0.5% 
triton X-100 (Sigma-Aldrich, St. Louis, MO), 0.54% ammonium chloride (Sigma-Aldrich, St. Louis, 
MO), and 0.07% porcine gelatin (Sigma-Aldrich, St. Louis, MO).  Sections were incubated overnight at 
room temperature with primary antibody at the following dilutions: 1:50 rabbit anti-VDR C-20 , 1:25 
Sheep anti-CYP27B1 , 1:25 goat anti-CYP24 G-15 , 1:1000 chicken IgY (or 1:400 rabbit  anti-peripherin, 
1:200 goat  or Sheep (Biomol) anti-CGRP.  Isolectin IB4 (IB4) conjugated to Alexa Flour 488 
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(Invitrogen, Carlsbad, Ca), which identifies unmyelinated sensory neurons that are responsive to the 
GDNF family of ligands (Ambalavanar and Morris 1993; Bennett, Michael et al. 1998), was added to 
slides for 20min between the primary and secondary antibodies at a concentration of 2μg/ml in PBS 
containing 1mM CaCl2 (Fisher Scientific, Pittsburgh, PA). Nuclei were stained with 400 nM 4',6-
diamidino-2-phenylindole (DAPI, Invitrogen, Carlsbad, CA) for 10 min before the addition of secondary 
antibodies. Secondary antibody incubations were conducted at room temperature for 2 hrs at the 
following concentrations: 1:200 goat anti-chicken IgY Cy2, 1:500 donkey anti-rabbit Alex Flour 647 
(Invitrogen, Carlsbad, CA), 1:200 donkey anti-sheep Cy3 (Jackson ImmunoResearch, West Grove, PA), 
1:1000 donkey anti-sheep Alexa Fluor 488 (Invitrogen, Carlsbad, CA), or 1:200 donkey anti-goat Cy3 
(Jackson ImmunoResearch, West Grove, PA).  All antibodies were diluted in PBS containing 23% 
donkey serum, and slides were rinsed between staining steps.  No staining was observed when primary 
antibodies were omitted and staining was almost completely abolished after preincubation of the primary 
antibodies with their blocking peptides.  
 
Neuronal Quantitation   
We quantitatively assessed immunoreactivity (ir) of vitamin D–related proteins and neural 
markers in the L5 DRG, because its relatively large size provides a substantial number of neurons to 
sample.  Moreover, L5 DRG should have very few, if any, projections to the ovary, reproductive tract, or 
incision sites and therefore should not be damaged by the ovariectomy procedure (Berkley, Robbins et al. 
1993; Steinman, Carlton et al. 1992; Takahashi, Chiba et al. 2003; Tanaka, Matsugami et al. 2002). (No 
gross differences were observed between staining in L5 and the other vertebral levels of DRG for any of 
the proteins examined.) For each stain, sections 250µm apart throughout each ganglion were imaged on a 
Nikon 80i fluorescent microscope.  A standard threshold value was visually determined for each stain, 
which appeared to differentiate real staining from background fluorescence.  This standard threshold 
value was used to create a mask for each image so that neurons with clear DAPI-stained nuclei and 
staining intensities above the standard threshold could be manually counted without bias using 
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Metamorph software.  Counting sections 250µm apart throughout the ganglion (3-5 sections) yielded an 
average of 428±42 total neurons with clearly stained nuclei for each DRG. We further assessed cell types 
in which vitamin D-associated proteins reside by co-immunostaining for peripherin, CGRP, or IB4 and 
using the same color thresholding techniques for merged images as described above.  We also 
characterized the intracellular localization of VDR to determine if;1) Intensely stained VDR-
immunoreactive aggregates were present within the DAPI-stained nuclear area, or 2) VDR-
immunoreactive-staining above the standard threshold was found outside the DAPI-stained nuclear area 
for each neuron.  For each animal and stain, percentages of labeled neurons were computed from averages 
of all sections analyzed, and data are presented as the mean + standard error. Significance (P<0.05) was 
determined by ANOVA followed by post-hoc analysis using Student-Newman-Keuls (SNK) or student’s 
t-test.  For publication images were pseudocolorized and adjusted for brightness and contrast. 
 
RESULTS 
 
Vitamin D-related proteins in dorsal root ganglia of rats at estrus 
Vitamin D receptor 
We assessed DRGs from intact female rats in estrus for the presence of VDRs. Western blots of 
total DRG protein revealed a strong band at approximately 60kDa. Two fainter bands were also 
consistently observed at 41kDa, and 24kDa and three very faint bands at 74kDa, 65kDa, and 50kDa could 
also be identified (Fig. 1).  Immunofluorescence of sectioned DRG revealed VDR-ir in neurons, but no 
VDR-ir surrounding the neurons or within central nerve bundles where satellite glia and Schwann cells 
are located (Fig. 2A).  Most neurons displayed VDR-ir localized to small nuclear aggregates; however, 
some neurons also had diffuse staining throughout the cell body or patchy membrane-localized staining. 
For this study we will refer to diffuse VDR-ir as cytoplasmic, although some of this staining may be 
confined to vesicles dispersed throughout the cytoplasm.   
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The percentage of total neurons with nuclear (nVDR) or cytoplasmic (cVDR) VDR-ir was 
quantified in L5 DRG (Fig. 2G).  About 71% of all neurons express nVDR, while 10% had cVDR 
staining and 8% had both nVDR and cVDR-ir. 
 To determine whether VDR is differentially expressed by small or large fiber neurons, DRG 
sections were co-immunostained for VDR and the small fiber specific intermediate filament peripherin 
(Fig. 3A).   Peripherin-positive and peripherin-negative neurons with clear DAPI stained nuclei were 
counted (DAPI-staining is not shown).  In intact rats, the percentage of neurons with nVDR did not differ 
between the peripherin-negative and peripherin-positive neuronal subpopulations (Fig. 3G).  On the other 
hand, cVDR was preferentially expressed by small fiber peripherin-positive neurons (Fig. 3H). The 
percentage of peripherin-ir neurons expressing cVDR was more than twice that of peripherin-negative 
neurons (p=0.002).  
 To determine whether VDR is differentially expressed by a specific subset of small fiber neurons, 
DRG sections were co-labeled for VDR and IB4 (Fig. 3B), which stains small fiber neurons responsive to 
the GDNF family of ligands, or CGRP (Fig. 3C), which is found in NGF-dependent neurons. nVDR 
expression did not differ between the two neuronal sub-types (Fig. 3I), while the percentage of CGRP 
neurons that expressed cVDR was almost three times that of IB4-positive neurons (Fig. 3J; p=0.016).  
 
CYP27B1  
We assessed whether DRG from intact female rats in estrus express CYP27B1, the enzyme that 
converts circulating 25(OH)D into active 1,25(OH)2D. Western blots revealed two bands that migrated at 
approximately 56kDa and 25kDa (Fig. 1). 
Immunofluorescent-staining of sectioned DRG revealed CYP27B1-ir in DRG neurons but not 
glia (Fig. 2B). CYP27B1-ir was diffuse throughout neural cell bodies.  The percentage of total neurons 
expressing CYP27B1 was about 22% (Fig. 2H). 
 DAPI-stained DRG sections were immunofluorescently-labeled for CYP27B1 and peripherin to 
determine whether CYP27B1 is differentially expressed by small or large fiber neurons (Fig. 4A, DAPI-
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staining is not shown).  The percentage of peripherin-ir neurons expressing CYP27B1 was more than 
three times that of peripherin-negative neurons (Fig 4G; p<0.001).  
DRG sections were immunofluorescently-labeled for CYP27B1 and IB4 (Fig. 4B) or CGRP (Fig. 
4C) to determine whether expression occurs in specific neuronal subsets. The percentage of CGRP-ir 
neurons that expressed CYP27B1 was more than two times the percentage of IB4-positive expressing 
CYP27B1 (Fig. 4H; p=0.003).  
 
CYP24 
Western Blot was used to determine whether DRG from intact female rats in estrus express 
CYP24, an enzyme involved in the degradation of 1,25(OH)2D and the production of other vitamin D 
metabolites.  A single faint band of the expected size of 55kDa was identified on western blots run with 
total DRG protein (Fig. 1).  
Immunofluorescence of sectioned DRG revealed CYP24-ir in DRG neurons but not glia (Fig. 
2C).  Like CYP27B1-ir, CYP24-ir was diffuse throughout neural cell bodies.  The percentage of total 
neurons with CYP24 was quantified in the L5 DRG of intact female rats in estrus.  About 17% of all 
neurons express CYP24 (Fig. 2I). 
 To determine whether CYP24 is differentially expressed by large or small fiber neuronal cell 
types, DRG sections were co-labeled for CYP24 and peripherin (Fig. 5A).  CYP24 was preferentially 
expressed by small fiber peripherin-positive neurons (Fig. 5G). The percentage of peripherin-ir neurons 
expressing CYP24 was one and a half times that of peripherin-negative neurons.  
 We assessed the extent to which CYP24 is expressed by peptidergic or non-peptidergic small 
fiber neurons.  DRG sections were immunofluorescently-labeled for CYP24 and CGRP (Fig. 5C) or IB4 
(Fig. 5B). The percentage of CGRP-positive neurons expressing CYP24 was about four times more than 
the percentage of IB4-positive neurons expressing CYP24 (Fig. 5H; p<0.001). 
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cVDR colocalizes with CYP27B1 and CYP24  
 Because cVDR, CYP27B1, and CYP24 were all preferentially expressed by peripherin-ir, CGRP-
ir neurons, we co-stained DRG for cVDR and CYP27B1 (Fig. 6A) or CYP24 (Fig. 6B) to determine if 
they are expressed within the same neurons.  Most neurons with cVDR-ir were observed to have 
CYP27B-ir and CYP24-ir, showing that neurons with cVDR typically have proteins necessary to locally 
regulate 1,25(OH)2D concentrations.  
 
Effect of ovariectomy (OVX) on Vitamin D-related proteins in dorsal root ganglia  
VDR  
Having verified that DRG neurons from intact female rats express VDR, CYP27B1, and CYP24, 
we assessed whether expression of these proteins is affected by OVX. We began by examining whether 
OVX alters VDR protein levels in total DRG lysates (Fig. 7A).  The only VDR isoform to change 
significantly following OVX was the 60kDa band, which was reduced by 51% compared to lysates from 
intact rats in estrus (p=0.037). 
Immunohistochemistry revealed that, as in intact rats, VDR-ir in ovariectomized rats was 
distributed in nuclear and cytoplasmic compartments in neurons, but not glia (Fig. 2D). Approximately 
66% of neurons in DRG from ovariectomized rats express nVDR, 8% express cVDR, and 6% express 
both (Fig. 2G); only the modest reduction in nVDR was significant (p=0.038). 
 DAPI-stained DRG sections from ovariectomized rats were co-labeled for VDR and peripherin 
(Fig. 3D). The percentage of peripherin-ir and peripherin-negative DRG neurons expressing nVDR in 
ovariectomized rats did not change (Fig. 3G).  However, the percentage of peripherin-ir neurons with 
cVDR was reduced, so that there was no longer any difference in the percentage of peripherin-ir and 
peripherin-negative neurons expressing cVDR in ovariectomized rats (Fig. 3H).  
DAPI-stained DRG sections from ovariectomized rats were co-labeled for VDR and IB4 (Fig. 
3E) or CGRP (Fig. 3F). The percentage of DRG neurons expressing nVDR in ovariectomized rats was 
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comparable in CGRP-ir and IB4-positive neurons (Fig. 3I).  However, there was a 63% decrease in the 
percentage of CGRP-ir expressing cVDR following OVX (Fig. 3J; p=0.009).  
 
CYP27B1  
Western blots of total DRG protein showed that while there was no change in expression of the 
25kDa CYP27B1 band, expression of the 56kDa CYP27B1 band dropped by 31% following OVX (Fig. 
7B; p=0.042).   
CYP27B1-ir in DRG from ovariectomized rats was found in neurons, but not glia (Fig. 2E). The 
average percentage of total neurons expressing CYP27B1 dropped from 22±4% to 10±2% following 
OVX, but this change did not achieve statistical significance (Fig. 2H; p=0.063). 
DAPI-stained DRG sections from ovariectomized rats were co-labeled for peripherin and 
CYP27B1 (Fig. 4D).  Ovariectomy did not affect the small proportion of peripherin-negative neurons 
expressing this enzyme. (Fig. 4G).  However, OVX resulted in a 57% decrease in proportion of 
peripherin-ir neurons expressing CYP27B1 (p=0.003) to a level comparable to that of peripherin-negative 
neurons (Fig. 4G).  
DAPI-stained DRG sections from ovariectomized rats were co-labeled for CYP27B1 and IB4 
(Fig. 4E) or CGRP (Fig. 4F).   Ovariectomy did not significantly alter the proportion of IB4-positive 
neurons expressing CYP27B1 (Fig. 4H).  In contrast, there was a 61% drop in the proportion of CGRP-ir 
DRG neurons with CYP27B1-ir after OVX (Fig. 4H; p<0.001), such that percentages of neurons 
expressing this enzyme were comparable in IB4 and CGRP-ir subpopulations.  
 
CYP24 
 Western blots of total DRG protein showed that there was no significant change in total CYP24 
levels following OVX (Fig. 7C).  As in rats at estrus, CYP24-ir was present exclusively in neurons (Fig. 
2F), and immunostaining showed no change in the percentage of total neurons expressing CYP24 
following OVX (Fig. 2I). 
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 DAPI-stained DRG sections from ovariectomized rats were co-labeled for peripherin and CYP24 
(Fig. 5D).  As with rats in estrus, CYP24-ir was preferentially expressed by small fiber peripherin-
positive neurons in OVX rats (Fig. 5G). Ovariectomy did not alter the proportion of peripherin-ir or 
peripherin negative neurons displaying CYP24-ir (Fig. 5G).  
 DAPI-stained DRG sections from OVX rats were co-labeled for CYP24 and IB4 (Fig. 5E) or 
CGRP (Fig. 5F).  As in estrus, CYP24-ir was present predominantly within CGRP-ir neurons, with only 
small numbers of IB4-positive neurons expressing this enzyme (Fig. 5H).  Ovariectomy did not alter 
numbers of either CGRP-ir or IB4-positive neurons expressing CYP24 (Fig. 5H).  
 
Changes in neural markers following ovariectomy 
We assessed whether changes in neuronal protein expression following OVX could contribute to 
observed differences in expression of vitamin D-related proteins.   The percentage of total neurons 
expressing peripherin was 63% in intact rats and underwent a small but significant decline to 59% 
following OVX (p=0.042, Table 1).   Within the peripherin-positive population of DRG neurons, OVX 
resulted in a 38% decline in the percentage of neurons expressing CGRP-ir, while the IB4-positive 
population was unaffected (Table 1).   
The small decrease in peripherin-positive neurons resulted in a proportional increase in 
peripherin-negative neurons , but the small numbers of these neurons expressing CGRP or IB4 were 
unaffected (Table 1).  The percentages of IB4-positive and CGRP-ir neurons that expressed peripherin-ir 
were unaltered by OVX (Tables 1). 
DISCUSSION 
 
 The central finding of this study is that adult rat sensory neurons express proteins associated with 
vitamin D signaling pathways.  Nuclear VDR is widely distributed within all types of DRG neurons 
suggesting broad transcriptional actions of this hormone.  Membrane and cytoplasmic VDR, perhaps 
indicative of rapid signaling pathways, is present selectively in unmyelinated, CGRP-ir neurons.  This 
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same subpopulation contains vitamin D metabolizing enzymes, implying close regulation of vitamin D 
metabolite levels. Ovarian hormones may play an important role in regulating neuronal responsiveness to 
1,25(OH)2D by up-regulating both its activating enzyme and its cytoplasmic receptor.  Because vitamin D 
deficiency is strongly associated with musculoskeletal pain and this is exacerbated by the loss of ovarian 
hormones, it is important to consider the role of these convergent systems in regulating nociceptor 
function. 
 
Vitamin D signaling in the central nervous system 
Vitamin D is becoming recognized as an important hormone in nervous system health.  VDR is 
expressed by neurons, oligodendrocytes, and astrocytes within the limbic system, basal ganglia, spinal 
cord, cerebellum, and cerebral cortex (Baas, Prufer et al. 2000; Eyles, Smith et al. 2005; Glaser, Veenstra 
et al. 1999; Neveu, Naveilhan et al. 1994; Perez-Fernandez, Alonso et al. 1997; Prufer, Veenstra et al. 
1999; Walbert, Jirikowski et al. 2001).  VDR localization within both neuronal nucleus and cytoplasm has 
been described (Glaser, Veenstra et al. 1999; Prufer, Veenstra et al. 1999; Racz and Barsony 1999).  
Studies have also shown that neurons and glia in brain express CYP27B1 (Eyles, Smith et al. 2005; 
Zehnder, Bland et al. 2001), and CYP24 mRNA has been detected in glioma and primary glial cell culture 
(Naveilhan, Neveu et al. 1993), suggesting that the brain can regulate local 1,25(OH)2D concentrations.  
Vitamin D signaling has been linked to cell survival, proliferation, and differentiation, and is especially 
important during brain development (Levenson and Figueiroa 2008).  In fact, gestational vitamin D 
deficiency is thought to be associated with long term cognitive disorders such as anxiety and 
schizophrenia (Levenson and Figueiroa 2008).  In the adult, vitamin D supplementation has been 
proposed to improve outcomes in multiple sclerosis, Parkinson’s disease, and traumatic brain injury 
(Cekic, Sayeed et al. 2009; Myhr 2009; Newmark and Newmark 2007).  Thus, accumulating evidence 
suggests that vitamin D signaling plays important roles in the central nervous system.  
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Vitamin D-related proteins in adult rat DRG 
Much less is known regarding the role of vitamin D in the peripheral nervous system. VDR has 
been identified in fetal (E12-E21) DRG neurons but not glia (Johnson, Grande et al. 1996; Veenstra, 
Prufer et al. 1998) (although VDR mRNA was reported in cultured sciatic nerve Schwann cells (Cornet, 
Baudet et al. 1998)).  However, the presence of VDRs and related proteins in the adult peripheral nervous 
system is not well documented. 
Our western blot findings show that VDR protein is present within adult rat DRG, and 
immunocytochemical analyses show that it is found in most neurons. VDR can regulate transcription by 
forming homodimers or heterodimers with 9-cis retinoid X receptor (RXR) which then translocate to the 
nucleus (Shaffer and Gewirth 2004).   Consistent with a transcriptional role, nuclear VDR was observed 
in the majority of DRG neurons as small discrete foci (Glaser, Veenstra et al. 1999; Prufer, Veenstra et al. 
1999); because these may be absent from a given section plane of a given neuronal nucleus, we may have 
underestimated their actual prevalence.  These foci are believed to represent binding of ligand-activated 
RXR/VDR heterodimers to DNA, thus corresponding to sites of transcription (Prufer, Racz et al. 2000).  
Because nuclear VDR was distributed widely throughout all DRG neural subtypes, VDR is likely to act as 
a classical transcription factor in most adult DRG neurons. 
We also observed a subset of neurons where VDR-ir was localized to the cytoplasm or plasma 
membrane.  While some of the cytosolic VDR could represent de novo synthesis or ligand-deficient VDR 
dimers (Prufer, Racz et al. 2000; Racz and Barsony 1999), another explanation is that this VDR fraction is 
involved in rapid signaling.  The most prominent band disclosed in DRG homogenates had a mass of 
60kDa, and this isoform reportedly is exclusive to membrane and cytosolic subcellular fractions 
(Gonzalez Pardo, Boland et al. 2008).  In cardiomyocytes, cVDR serves as a reserve which, upon 
1,25(OH)2D binding, translocates to cardiac t-tubules (Tishkoff, Nibbelink et al. 2008).  The patchy VDR-
ir pattern localized to the plasma membrane of some DRG neurons suggests a distribution to distinct 
membrane microdomains, and is consistent with a role for VDR in rapid signaling in sensory neurons 
(Huhtakangas, Olivera et al. 2004).  For example, 1,25(OH)2D can influence calcium channel activity, 
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leading to rapid increases in intracellular calcium concentration and production of second messengers 
(Losel, Falkenstein et al. 2003).  Thus, in addition to its transcriptional role within all DRG neuronal 
populations, VDR may exert rapid signaling in a selected subpopulation of neurons. 
 
VDR signaling in DRG neuronal subpopulations 
Selective neuronal markers provide insight as to how VDR signaling may vary as a function of 
neuronal subtype.  Neurons lacking the intermediate filament protein peripherin are predominantly large 
myelinated neurons (Goldstein, House et al. 1991), which are involved in tactile sensation and 
proprioception (Casellini and Vinik 2007; Muller, Ryals et al. 2008; Nardone, Galante et al. 2007).   
These neurons contained nVDR but were mostly devoid of both CYP27B1-ir and CYP24-ir.  This implies 
that large sensory neurons may be influenced by VDR transcriptional signaling, but that VDR activation 
is determined passively by levels of circulating 1,25(OH)2D, as they likely lack the ability to regulate 
local 1,25(OH)2D levels. The functional significance of this signaling pathway is unclear, but it is 
noteworthy that vitamin D deficiency in humans is associated with increased incidence in falls (Bischoff-
Ferrari, Dawson-Hughes et al. 2004; Faulkner, Cauley et al. 2006), which may suggest altered 
proprioceptive function of large sensory fibers.  
Neurons containing peripherin-ir represent unmyelinated C-fibers, which are associated with 
chemoreception, thermal sensation, and pain, burning and itching.  As with large myelinated neurons, the 
majority of these also showed VDR-ir localized to the nucleus.  However, these peripherin-ir neurons also 
include the subgroup in which VDR is localized to the cytoplasm, most often in conjunction with nuclear 
staining.  It is well known that C-fiber neurons can be further characterized based on their neurotrophin 
dependencies and peptide content, and our colocalization studies show that the cytoplasmic form of VDR 
is distributed selectively in the NGF-dependent, CGRP-ir neurons, with approximately one third 
displaying cVDR; these neurons conduct information regarding pain and temperature, and antidromically 
release neuropeptides that promote vasodilation and extravasation, thus contributing to inflammation 
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(Birklein and Schmelz 2008).  These findings suggest that vitamin D can activate multiple signaling 
pathways, which may functionally influence a subpopulation of neurons with pain-sensing capabilities.  
Our observations regarding VDR distribution in the DRG suggest that some neurons may be more 
strongly influenced by vitamin D than others.  If so, then local vitamin D metabolite levels for those 
neurons may require closer regulation.  Findings concerning vitamin D-related proteins provide evidence 
that this is the case.  Hence, the prohormone converting enzyme CYP27B1 is enriched specifically in 
peripherin-ir, CGRP-ir neurons, as is CYP24, which could be involved in the inactivation of 1,25(OH)2D 
or perhaps the formation of other metabolites such as 24,25(OH)2D3.  Further, these enzymes co-localize 
selectively within neurons displaying cytoplasmic VDR.  Collectively, these findings are consistent with 
the hypothesis that DRG peptidergic neurons possess vitamin D signaling pathways, whose gain can be 
modulated by altering levels of cVDR, or by regulating levels of vitamin D metabolic enzymes. 
 
Regulation of VDR and CYP27B1by ovarian hormones 
 One likely factor in regulating vitamin D-related proteins in DRG is female reproductive 
hormone status.  Ovarian hormones have been found to promote the formation of 1,25(OH)2D by 
enhancing CYP27B1 expression and by inhibiting the expression of CYP24 (Lechner, Bajna et al. 2006; 
Tanaka, Castillo et al. 1978).  They are also reported to promote the expression of VDR (Gilad, Bresler et 
al. 2005). In cancer models there has been some progress in uncovering how estradiol regulates VDR 
expression. Estradiol binds membrane bound ERβ receptors, which signal through ERK1/2 to increase 
transcripton of VDR (Gilad, Bresler et al. 2005).  Research from another group has shown that estrogen 
may regulate VDR promoter activity of exon 1C through SP1 sites, which can be mediated through ERα 
or ERβ (Wietzke, Ward et al. 2005). To determine whether ovarian hormones regulate VDR or enzyme 
expression in DRG neurons, we compared vitamin D-related protein expression in DRG from cycling rats 
at estrus to that of ovariectomized rats.  Estrus occurs several hours after the natural surge in reproductive 
hormones including estradiol, progesterone, and prolactin (Freeman 1994), when hormone-responsive 
changes in protein expression are most apt to be evident.  In contrast, rats following OVX have sustained 
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depression of ovarian hormones similar to that which occurs naturally in menopause, albeit occurring at a 
younger age and more abruptly than would occur normally.   
Consistent with reported findings for other tissues, OVX resulted in decreased expression of VDR 
and CYP27B1.  In protein blots, the cytoplasm/membrane-specific 60kDa isoform of VDR was reduced 
by 51%, and the 56kDa full length CYP27B1 band was reduced by 31%.  Immunofluorescence 
examination showed that the numbers of neurons with cVDR and CYP27B1 expression were both 
diminished, and this decrease occurred exclusively within the peripherin-ir, CGRP-ir population.  In 
contrast, no significant changes occurred in nVDR or CYP24.  Therefore, based on these findings in OVX 
rats, a decline in ovarian hormones would not only down-regulate cVDR expression, but would also 
decrease the amount of CYP27B1 available to convert prohormone to active 1,25(OH)2D.  At the same 
time, levels of the CYP24 remain unchanged, thereby favoring a reduction in levels of 1,25(OH)2D.  
Accordingly, low ovarian hormone levels may impair vitamin D signaling in peptidergic nociceptor 
neurons by diminishing levels of both cyotplasmic receptor and ligand. 
 While these observations are consistent with a reduction in the numbers of neurons in which 
cVDR signaling occurs, a caveat is that changes in reproductive hormones could influence marker 
expression, thereby introducing error to our counts of neuronal subpopulations containing vitamin D-
related proteins.  While hormone-related changes in IB4-positive neurons have not been reported (and 
were not detected here), it is known that estrogens increase CGRP expression (Gangula, Lanlua et al. 
2000; Mowa, Usip et al. 2003).  Consistent with these reports, we found that OVX resulted in a reduction 
of roughly 1/3 in the number of neurons expressing CGRP-ir.  Of those retaining the CGRP phenotype, 
cVDR and activating enzyme expression were reduced by over 60%. This occurred without concomitant 
increases in cVDR or CYP27B1 in other cell phenotypes that might imply changes due to altered marker 
expression.  It therefore appears that ovarian hormone deficiency selectively affects a subpopulation of 
DRG neurons, where both peptide phenotype and VDR signaling are dramatically reduced. 
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Vitamin D, ovarian hormones, and pain 
 While an association between pain and vitamin D deficiency has been observed for at least 20 
years (Masood, Narang et al. 1989), this is often attributed to bone and muscle pathologies.  Muscle 
symptoms, including pain, precede the appearance of biochemical indicators of bone pathology (Glerup, 
Mikkelsen et al. 2000; Masood, Narang et al. 1989), suggesting that bone is not the only source of 
musculoskeletal pain.  Vitamin D deficiency does lead to atrophy of type II muscle fibers (Glerup, 
Mikkelsen et al. 2000);  however, type II muscle fiber atrophy is non-specific and does not in itself cause 
pain (Mastaglia and Hilton-Jones 2007).  Based on our findings, it seems likely that vitamin D may act 
directly on sensory nerves to modulate pain.  Moreover, the extent to which vitamin D deficiency 
produces musculoskeletal pain appears to be strongly linked to estrogen status.  For example, 
musculoskeletal pain occurs commonly in hypoestrogenemia resulting from naturally occurring 
menopause (Andersson, Ejlertsson et al. 1993; Bergman, Herrstrom et al. 2001; Croft, Rigby et al. 1993; 
Dugan, Powell et al. 2006; Greendale, Reboussin et al. 1998; White, Speechley et al. 1999; Wolfe, Ross 
et al. 1995) or pharmacotherapy using aromatase inhibitors or gonadotropin-releasing hormone agonists 
(Felson and Cummings 2005; Friedman, Juneau-Norcross et al. 1993; Garreau, Delamelena et al. 2006; 
Morales, Pans et al. 2006; Mouridsen 2006).  Musculoskeletal pain associated with menopause is 
ameliorated by hormone replacement therapy (Dugan, Powell et al. 2006), implying a direct link between 
pain and hormone levels.  It is not clear why musculoskeletal pain occurs with hypoestrogenemia.  
However, low estrogen levels following aromatase inhibition are accompanied by low serum 25(OH)D 
levels, and high dose vitamin D3 supplementation partially reverses the discomfort (Khan, Reddy et al. 
2009; Waltman, Ott et al. 2009), consistent with a link among estrogens, vitamin D and pain.  However, it 
should be noted that high dose vitamin D3 treatment does not fully alleviate pain symptoms.  This may 
not be surprising given our findings that low ovarian hormone levels are also associated with diminished 
DRG neuronal expression of VDR and CYP27B1. Thus, hypoestrogenemia might hinder conversion of 
the therapeutic supplement to the active hormone and limit receptor-mediated signaling, thereby 
rendering dietary supplementation less effective.   Collectively, these studies and the present findings 
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underscore a need for additional research clarifying the relationships among vitamin D, steroid hormones, 
and sensory pathways. 
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TABLES 
 
 
 
 
 
 
 
 
Table 1. Quantitative analysis of neuronal markers and effect of ovariectomy. This table shows the 
percentages of total neurons, peripherin-positive neurons, peripherin-negative neurons, 
CGRP-positive neurons, or IB4-positive neurons that express peripherin, CGRP, or IB4. % 
Estrus (% OVX). There was a significant drop in the percentage of total neurons expressing 
peripherin and peripherin-positive neurons co-expressing CGRP following ovariectomy, 
p=*0.042 and **0.049 by student’s t-test. 
  
 
Total 
neurons 
% 
Peripherin-
positive neurons 
% 
Peripherin-
negative neurons 
% 
IB4 
neurons 
% 
CGRP 
neurons 
% 
Peripherin *63±1 *(59±1) 
100 
(100) 
0 
(0) 
90±2 
(85±3) 
85±2 
(76±4) 
IB4 35±2 (36±2) 
54±4 
(57±1) 
9±2 
(11±2) 
100 
(100) 
Not 
determined 
CGRP 43±7 (28±3) 
**55±9 
**(34±3) 
18±2 
(19±4) 
Not 
determined 
100 
(100) 
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FIGURES 
Figure 1. 
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Figure 1. VDR, CYP27B1, and CYP24 proteins are present in adult DRG. Western blots of 
extracted DRG proteins from intact rats in estrus were probed for VDR, CYP27B1, or CYP24. 
Samples were run alongside molecular markers in order to estimate protein size. Images are cropped 
to show representative lanes. 
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Figure 2. 
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Figure 2. Cellular localization of VDR, CYP27B1, and CYP24 in adult DRG. Cryosections of L5 
DRG from intact rats in estrus (A-C) or ovariectomized (OVX) rats (D-F) were immunofluorescently 
labeled for VDR (A&D; red), CYP27B1 (B&E; red), or CYP24 (C&F; red), and nuclei were stained 
with DAPI (shown only in the insets of A and D; blue). Examples of neurons with nuclear-localized 
VDR are indicated in A and D by arrow heads, and neurons with intense cytoplasmic VDR staining 
are indicated by arrows. The insets show magnified examples of neurons with nuclear or nuclear and 
cytoplasmic VDR immunoreactivity. In B& E, examples of neurons with intense labeling for 
CYP27B1 are indicated by arrows. In C & F, neurons with intense labeling for CYP24 are indicated 
by arrows. In A-F staining is not consistent with glial expression of VDR, CYP27B1, or CYP24 (ie. 
No staining surrounding neurons in satellite glia or in the Schwann cells of outlined nerve bundles 
(NB)). In G, the total proportion of neurons expressing VDR in estrus or after OVX is presented. 
The shaded area within each bar represents the proportion of neurons with both cytoplasmic and 
nuclear VDR staining. Significant differences between individual groups are shown by bracketing, 
p= *<0.001 and **0.038. The overall difference between Estrus and OVX expressing VDR was also 
significant, p=0.028. H and I present quantitative analysis of the percentages of neurons 
immunostained for CYP27B1 and CYP24, respectively. Scale bar = 100μm (10μm in insets). 
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Figure 3. 
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Figure 3. Cellular colocalization of VDR with the neural markers peripherin, IB4, and CGRP. 
Cryosections of L5 DRG from intact rats in estrus (A-C) or ovariectomized rats (D-F) were 
immunofluorescently-labeled for VDR (A-F; red) and peripherin (A&D; green), IB4 (B&E; green), 
or CGRP (C&F; green), and the nuclei were stained with DAPI (A-F not shown). Neurons with 
nuclear VDR and neural markers are indicated by arrowheads, and neurons with cytoplasmic VDR 
and neural markers are indicated by arrows. G-J: The mean percentages of neurons with neural 
marker immunoreactivity that express nVDR or cVDR are presented in graphical form. Significant 
differences between individual groups are shown by bracketing, p= H) *0.002, J) *0.016 and 
**0.009. Overall differences between neural markers were significant for H) cVDR peripherin (+) 
vs. peripherin (-) (p=0.001) and J) cVDR IB4 vs. CGRP (p=0.039). Overall differences between 
Estrus and OVX were also significant J) p=0.027. Scale bar = 50μm. 
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Figure 4. 
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Figure 4. Cellular colocalization of CYP27B1 with the neural markers peripherin, IB4, and CGRP. 
Cryosections of L5 DRG from intact rats in estrus (A-C) or ovariectomized rats (D-F) were 
immunostained for CYP27B1 (A-F; red) and peripherin (A&D; green), IB4 (B&E; green), or CGRP 
(C&F; green), and the nuclei were stained with DAPI (A-F not shown). Neurons with intense 
CYP27B1 and neural marker staining are indicated by arrows. G-J: The mean percentages of neurons 
with neural marker immunoreactivity that express CYP27B1 are illustrated in graphical form. 
Significant differences between individual groups are shown by bracketing, p= G) *<0.001 and 
**0.003, H) *0.003 and <0.001. Overall differences between neural markers was significant for G) 
CYP27B1 peripherin (+) vs. peripherin (-) (p<0.001) and J) CYP27B1 IB4 vs. CGRP (p=0.005). 
Overall differences between Estrus and OVX were also significant G) p=0.005 and J) p=0.001. 
Scale bar = 50μm. 
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Figure 5. 
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Figure 5. Cellular colocalization of CYP24 with the neural markers peripherin, IB4, and CGRP. 
Cryosections of L5 DRG from intact rats in estrus (A-C) or ovariectomized rats (D-F) were 
immunostained for CYP24 (A-F; red) and peripherin (A&D; green), IB4 (B&E; green), or CGRP 
(C&F; green), and the nuclei were stained with DAPI (A-F not shown). Neurons with intense CYP24 
and neural marker staining are indicated by arrows. G&H: The mean percentages of neurons with 
neural marker immunoreactivity that express CYP24 are illustrated in graphical form. Significant 
differences between individual groups are shown by bracketing, p= G) *0.024 and **0.005, J) 
*<0.001 and **0.001. Overall differences among neural markers were significant for G) CYP24 
peripherin (+) vs. peripherin (-) (p=0.005) and J) CYP24 IB4 vs. CGRP (p<0.001). Scale bar = 50μm 
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Figure 6. 
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Figure 6. Cellular colocalization of VDR with the enzymes CYP27B1 or CYP24. Cryosections of 
L5 DRG from rats in estrus were immunostained for VDR (red) and the enzymes CYP27B1 (A) or 
CYP24 (B) (green) and nuclei were stained with DAPI (not shown). Neurons co-labeled for each 
enzyme and cVDR are indicated by arrows. Scale bar = 50 μm. 
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Figure 7.  
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Figure 7. DRG expression of VDR and CYP27B1, but not CYP24 is reduced following 
ovariectomy. Western blots of proteins extracted from DRG of intact rats in estrus or ovariectomized 
rats were probed for VDR (A), CYP27B1 (B), or CYP24 (C) and GAPDH (A-C) as a loading 
control. A) The 60kDa band of VDR showed a significant decrease in intensity following 
ovariectomy. B) The 56kDa band of CYP27B1 also showed a significant drop in intensity following 
ovariectomy. C) There was no significant change in CYP24 after ovariectomy. OVX n=5, Estrus 
n=4, 2-3 replicates per animal were averaged. Significance determined by student’s t-test.  
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CHAPTER 3. VITAMIN D DEFICIENCY PROMOTES SENSORY AXON SPROUTING AND 
MUSCLE HYPERSENSITIVITY 
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ABSTRACT 
Musculoskeletal pain affects 35-50% of adults, most of whom are vitamin D deficient.  Previous findings 
from this laboratory have demonstrated that putative nociceptors express vitamin D receptors (VDRs), 
suggesting that vitamin D metabolites can act directly on sensory nerves.  In this study, 2-4 weeks of a 
vitamin D deficient diet produces deep muscle mechanical hypersensitivity in rats that is not corrected by 
dietary calcium supplementation. This hypersensitivity to deep pressure is accompanied by nociceptor 
hyperinnervation of the muscle.  In culture, VDRs are enriched in small fiber sensory growth cones and 
rapid response receptors regulate neurite growth consistent with in vivo findings.  Because vitamin D 
metabolites directly inhibit axonal growth of sensory c-fibers, vitamin D deficiency leads to muscle 
hyperinnervation, which may contribute to musculoskeletal pain. 
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INTRODUCTION 
Vitamin D recently has been proposed to play wide ranging roles in human health, and 
deficiencies in this secosteroid are implicated in chronic musculoskeletal pain (Benson, Wilson et al. 
2006; de Torrente de la Jara, Pecoud et al. 2006; Glerup and Eriksen 1999; Gloth, Lindsay et al. 1991; 
Heidari, Shirvani et al. 2010; Macfarlane, Palmer et al. 2005; McBeth, Pye et al. 2010; Plotnikoff and 
Quigley 2003) and an increased risk of falling (Annweiler, Montero-Odasso et al. 2010).  27.5-36% of 
adolescents and 35-50% adults suffer from chronic musculoskeletal pain (Bergman 2007; De Inocencio 
2004) and up to 93% of them may be vitamin D deficient, with levels of serum 25-hydroxyvitamin D 
(25(OH)D) less than 20ng/ml (50nmol/L) (Plotnikoff and Quigley 2003).  Some studies show that this 
pain may be relieved by vitamin D supplementation (de Torrente de la Jara, Pecoud et al. 2006; Glerup 
and Eriksen 1999; Gloth, Lindsay et al. 1991). However, it is difficult to establish a causal relationship, as 
the incidence of musculoskeletal pain is increased in people that are older, have a higher body mass 
index, and spend less time out-of-doors, all factors contributing to vitamin D deficiency (Bergman 2007; 
Yetley 2008).   
While vitamin D could affect pain sensitivity at multiple sites, we found recently that small 
unmyelinated dorsal root ganglion (DRG) sensory neurons express both nuclear and 
membrane/cytoplasmic vitamin D receptors (VDRs) (Tague and Smith 2010), suggesting that sensory 
neurons, including putative nociceptors, are direct targets of an active vitamin D hormone, 1,25-
dihydroxyvitamin D (1,25(OH)2D).  In order to further investigate the relationship between vitamin D and 
musculoskeletal pain, a rat model in which vitamin D deficiency is reliably induced was used.  Reducing 
dietary intake of vitamin D can induce persistent vitamin D deficiency in laboratory rats (Weishaar and 
Simpson 1987).  However, vitamin D deficiency, in turn, leads to reductions in serum calcium that can 
affect many physiological functions independently (Johnson and DeLuca 2002; Uhland, Kwiecinski et al. 
1992; Weishaar and Simpson 1987), although this can be corrected by administering a diet high in 
calcium and phosphate (Weishaar and Simpson 1987).   
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MATERIALS AND METHODS 
Animals and diets 
All animal protocols and procedures were in accordance with the NIH guidelines for the care and use of 
laboratory animals and were approved by the University of Kansas Medical Center Animal Care and Use 
Committee.  Fifteen weaned (24 day-old) female Sprague Dawley (Harlan) rats were housed 2-3 per cage 
in forced-air-ventilated micro-isolation cages with a 14hr light/10hr dark light cycle and fed ad libitum a 
normal chow diet.  At the age of 31 days, rats were anaesthetized with ketamine 70mg/kg (Pfizer)/ 
xylazine 6mg/kg i.p. (Lloyd Laboratories) and ovariectiomized via bilateral hindflank incision.  Upon 
waking, and at 24hr and 48hr post-operation, rats were administered ketoprofen 5mg/kg s.c. (Ketofen; 
Fort Dodge Animal Health) as an analgesic.  At 48 days of age, rats were randomly separated into three 
groups and fed one of three diets (blinded); Control: 2.2 IU/g vitamin D (cholecalciferol), 0.47% Ca, 
0.3% P (Harlan Teklad, TD.07370), VD-/+ Ca: No vitamin D, 2.5% Ca, 1.5% P (Harlan Teklad, 
TD.07541), VD-: No vitamin D, 0.47% Ca, 0.3% P (Harlan Teklad, TD.89123). Food was provided in a 
ceramic bowl on the cage floor and replaced twice weekly.  Rats were weighed weekly and food was 
weighed before and after changing (only data for week 0, 2, and 4 are presented in Table 1).  Rats were 
maintained on their assigned diet for four weeks.  After two weeks on the diet, one to two ml of blood 
was drawn from the tail vein.  Serum was collected and stored at -20 ºC. At the end of the study, rats were 
anaesthetized with ketamine 70mg/kg / xylazine 6mg/kg (i.p.), thoracic cavities were opened, blood was 
removed via cardiac puncture, and the rats were perfused with 50ml of cold 0.9% saline containing 
10units/ml heparin (APP Pharmaceuticals) at a rate of 40ml/min, followed by 150-200ml of 4% 
formaldehyde (prepared in PBS from paraformaldehyde (Sigma-Aldrich)).  Serum was collected and 
stored at -20C. See S1 for an overview of the experimental timeline. 
Behavioral testing 
All behavioral testing was performed in a quiet room under normal fluorescent lighting six to eight hours 
into the light cycle.  The rat cages were moved to the behavior room 1hr before testing.  All statistical 
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analysis of behavior was conducted using two way repeated measures ANOVA with Student-Newman-
Keuls multiple comparisons.   
Muscle mechanical sensitivity- The muscle compression test used in this study is similar to that of models 
previously described (Sharma, Ryals et al. 2009; Skyba, Radhakrishnan et al. 2005).  A digital Randall 
Selitto instrument (IITC Life Science Inc) with a plastic cap with a 0.5cm wide surface area (S2) was 
used.  During the week prior to diet manipulation, rats were habituated to a rat sling (IITC Life Science, 
Inc) for 5min on two separate days.  The day prior to starting the diets, and each week thereafter, rats 
were stabilized in the rat sling to allow free access to the hind limbs.  While holding the left hind paw, the 
flat side of the probe was placed against the inner left calf, while the capped pressure sensor was placed 
on the center of the left exterior calf muscle.  The instrument was slowly compressed until the rat 
attempted a limb withdrawal (or vocalized).  The calf was compressed three times and the maximum 
force applied each time was recorded and averaged.  To minimize stress, rats were restrained in the sling 
for no longer than 3min/week.  To ensure that the same part of the calf muscle was compressed each time, 
the left calf was shaved each week 3 days before muscle compression under brief isoflurane anesthesia.  
During week four, after initial testing, 2.5% lidocaine/2.5% prilocaine cream (TOLMAR Inc.) was 
applied to the calf skin for 30 minutes and muscle sensitivity measurements were repeated.  Similar to 
previous reports (Skyba, Radhakrishnan et al. 2005), there were no significant differences in muscle 
sensitivity before and after cutaneous lidocaine treatment (data not shown), verifying that this test 
measures deep tissue pressure sensitivity and not cutaneous mechanical sensitivity.  
Cutaneous mechanical sensitivity- Cutaneous mechanical sensation was measured using a calibrated 4g 
monofilament. Rats were placed on a wire-mesh grid with plexiglass dividers and allowed to habituate for 
20min.  The monofilament was applied to the plantar surface of the hind paw five times per trial for a 
total of three trials.  The number of positive responses was recorded, and the percent withdrawal response 
for each paw was calculated.  A response was considered positive when the rat retracted its hind paw in 
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response to the monofilament.  The results shown are averages from the left and right hind paws.  
Cutaneous sensitivity was measured two days before starting diet manipulation and each week thereafter. 
Balance and motor co-ordination - An elevated, 2.5 cm wide round dowel was suspended between two 
support stands with an enclosed plastic platform at the one end.  Rats were trained at the ages of 28, 39, 
and 41 days to walk across the beam into the platform box, by placing them on the beam at increasing 
distances from the box, until they voluntarily walked the full 110cm of the beam.  Two days before 
starting the diets, and at week 2 and 4, rats were videotaped for three beam walk trials.  The videos were 
analyzed to determine the number of hind paw footfall slips per beam walk, which were then averaged. 
Muscle weakness - - Three days before starting the diets, and at weeks 2 and 4, rats were placed on a wire 
grid attached to a digital force gauge (San Diego Instruments).  The maximum grip force applied by the 
forelimbs was measured as the rats were gently pulled by the base of their tail until their grip was broken.  
This was repeated three times for each rat and the maximum force was recorded. 
General locomotor activity - Rats were placed in a Force Plate Actimeter (BASi) (Fowler, Birkestrand et 
al. 2001) and allowed to move freely for 5min.  Movements were detected by force transducers and 
recorded by a computer and rearing events were recorded by the investigator.  
Serum Measurements 
Serum 25-hydroxyvitamin D was measured by direct ELISA (Immunodiagnostik) according to 
manufacturer instructions. Serum calcium and phosphorous was measured by an outside laboratory 
(Physicians Reference Laboratory, L.L.C) by spectrophotometry.   
Tissue processing  
The left calf muscles (gastrocnemius and soleus) were removed and post-fixed in Zamboni’s fixative 
overnight at 4ºC.  Weight and volume (determined by fluid displacement in a graduated cylinder) were 
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recorded.  The muscles were washed for two weeks and cryoprotected at 4ºC in phosphate buffered saline 
containing 30% sucrose changed daily.  The entire calf was cut in the transverse plane at 25%, 50%, and 
75% of the way through the muscle.  The muscle was embedded in tissue freezing media (Electron 
Microscopy Science), frozen in liquid nitrogen-cooled isopentane, and stored at -80oC.   
The left tibia was removed and post-fixed in Zamboni’s fixative overnight at 4ºC.  The bones were 
washed at 4ºC in PBS changed daily for three days, then decalcified in PBS containing 10% EDTA for 
two weeks at 4ºC.  The decalcified bones were then cryoprotected overnight at 4ºC in PBS containing 
30% sucrose.  The bone was cut in half along the transverse plane.  The proximal portion was cut in half 
along the sagittal plane and the medial portion was embedded in tissue freezing media for sagittal 
sectioning of the epiphyseal plate.  The distal half of the bone was embedded in tissue freezing media for 
transverse sections of the diaphysis.  Bones were frozen on dry ice and stored at -80oC.  
Immunostaining of nerve fibers in muscle 
Thawed 20µm cryosections of muscle were immunoflourescently labeled.  Slides were incubated in pre-
incubation solution (1.5% donkey serum (Jackson ImmunoResearch), 0.5% gelatin (Sigma-Aldrich), and 
0.5% Triton X-100 (Sigma-Aldrich) prepared in Superblock (Thermo Scientific) for 1hr at room 
temperature.  Primary and secondary antibodies were diluted in incubation solution (50% preincubation 
solution, 50% Superblock).  Primary antibodies were incubated overnight at room temperature and 
secondary antibodies incubated for two hours.  Before and after the secondary antibody, slides were 
washed in PBS containing 0.25% Triton-X 100.  Slides were then dipped in distilled water and mounted 
with coverslips using 50% glycerol in PBS.  Primary and secondary antibodies were diluted as follows: 
1:500 chicken anti-peripherin (Chemicon), 1:200 sheep anti-CGRP (Biomol),  1:1,000 rabbit anti-
VMAT2 (Chemicon), or 1:1,500 rabbit anti-NFH (Sigma), 1:1,500 donkey anti-chicken DyLight 488 
(Jackson), 1:750 Donkey anti-sheep Dylight 649 (Jackson),  1:1,000 donkey anti-rabbit 647 (Invitrogen).   
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Quantitation of innervation density 
Images were taken (blinded) from transverse sections of the left lateral gastrocnemius muscle, which is 
located on the outside of the calf where most of the force was applied during muscle compressions.  A 
total of 18 images were taken per animal, 6 each from three levels at 25%, 50%, and 75% through the 
proximo-distal extent of the muscle using a Nikon 80i epifluorescent microscope.  A stereological grid 
was superimposed over the images, and numbers of grid intersections overlying immunoflourescently-
labeled axons was counted and divided by the total number of tissue intersections, to provide the apparent 
percentage area occupied by nerves (Clarke, Bhattacherjee et al. 2010).  Statistical analysis was 
conducted using one way ANOVA and Student-Newman-Keuls multiple comparisons. 
Bone measurements 
Hematoxylin and eosin-stained 20µm sections of bone were analyzed.  For growth plate analysis,  three 
fully visible chondrocyte columns in the center of each section were analyzed for height and cell number 
and averaged per section.  The transverse bone sections of the diaphysis were analyzed for bone 
circumference and bone marrow area.  Statistical analysis was completed with one way ANOVA and 
Student-Newman-Keuls multiple comparisons. 
Primary neuronal cell cultures 
Sensory:  DRG were removed from six week old female Sprague Dawley rats, dissociated with 2 units/ml 
dispase (ICN Biomicals Inc) and 2mg/ml collagenase type 1A (Sigma) and plated on glass coverslips 
(Bellco) coated with poly-D-lysine (Sigma) and laminin (Invitrogen) in 24-well culture dishes.  Cultures 
were maintained in Neurobasal A media (Invitrogen) containing 1mM glutamine (Sigma), 2% B27 
(Gibco), 100µg/ml primocin (InvivoGen), 20µM FrdU (Sigma) and 20µM uridine (Sigma) for 4 days, 
with concentrations of 1,25(OH)2D3 or JN that ranged from 0-100pM.  Cultures were incubated at 37ºC 
with 5% CO2 and media was changed after 24hrs and 72hrs.  Cultures were fixed in 4% formaldehyde for 
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one hour, DAPI stained, and immunofluorescently-labeled for peripherin (chicken 1:1000, Chemicon), 
NFH (mouse 1:200, Sigma), or VDR (rabbit 1:25, GeneTex) peripherin and GAP43 (mouse 1:240, 
Zymed).  Cultures were grown in triplicate and repeated twice.   
Sympathetic:  Superior cervical ganglia were removed from one day-old rats, dissociated with 0.25% 
trypsin-EDTA (Gibco) and collagenase 1A (Sigma) and plated on poly-D-lysine and laminin-coated 
coverslips.  Cultures were maintained in Neurobasal A media as described above with the addition of 
10µg/ml NGF (Alomone Labs) for 48 hours, with 0, 20pM or 100pM of 1,25(OH)2D3.  Cultures were 
fixed in 4% formaldehyde, DAPI stained and immunofluorescently-labeled for peripherin and VDR.  
Cultures were grown in triplicate and repeated twice.   
Neurite area quantitation 
A stereological grid was superimposed over culture images and the number of times a grid intersection 
crossed an immunofluorescently-labeled nerve fiber was counted and divided by the total number of 
intersections within each field to provide neurite area; this was divided by the number of viable neurons, 
determined by DAPI staining, to provide an estimate of neurite area per neuron.  Statistical analysis was 
completed with one way ANOVA and Student-Newman-Keuls multiple comparisons.   
 
RESULTS AND DISCUSSION 
To assess how vitamin D deficiency alters deep muscle sensitivity to noxious mechanical stimuli, 
Sprague Dawley rats were fed chow deficient in vitamin D, with or without high levels of calcium.  
Starting at seven weeks of age, rats were fed ad libitum, for four weeks, one of three blinded diets: 
control, vitamin D deficient with increased calcium and phosphate (VD-/+Ca), or vitamin D deficient 
with normal levels of calcium and phosphate (VD-) (Table 1). The VD-/+Ca diet was based on previously 
published reports that increasing dietary Ca from 0.47% to 2.5% normalizes serum Ca in vitamin D 
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deficiency (1.5% P is needed as a counterbalance)(Weishaar and Simpson 1987). Female rats were 
ovariectomized 2.5 weeks prior to initiation of the diet to remove the influence of cycling ovarian 
hormones on behavioral sensitivity testing (Craft 2007) and VDR expression in sensory nerves (Tague 
and Smith 2010).  Additionally, the incidences of vitamin D deficiency and musculoskeletal pain are high 
in women and tend to be associated with suppressed ovarian hormones (i.e. post-menopause, 
pharmacologically-induced estrogen suppression) (Alexander, Dennerstein et al. 2007; Gaugris, Heaney 
et al. 2005; Khan, Reddy et al. 2010). Rats were housed under normal fluorescent lighting with a 14 hr 
light/10 hr dark cycle. Rats fed vitamin D-deficient diets showed weight gains comparable to control 
subjects over the 4-week study (Table 1). However, food consumption was increased in the VD-/+Ca 
group throughout the study and in the VD- group at week four (Table 1).  To confirm vitamin D 
deficiency, blood was drawn at 2 weeks from the tail vein and at 4 weeks via cardiac puncture.  25(OH)D 
serum concentrations in both VD-/+Ca and VD- rats were reduced below 25nmol/L by week 2 and below 
10nmol/L by week 4 (Table 1).  In addition, serum Ca and P levels at week four were not reduced even 
though Ca is reported to be decreased in VD- rats after longer intervals (Weishaar and Simpson 1987).  
To determine whether vitamin D deficiency causes increased mechanical muscular sensitivity, we 
used a behavioral testing paradigm developed for this purpose (Sharma, Ryals et al. 2009; Skyba, 
Radhakrishnan et al. 2005).  Rats were placed weekly in a restraining sling allowing free access to their 
limbs.  While holding the left foot, the left calf muscle was compressed using a modified digital Randall-
Selitto testing device (S2) until the rat attempted to withdraw the limb or vocalized withdrew (or 
vocalized), and the maximum force applied by the testing device was recorded.  Between 0 and 2 weeks, 
the force required to elicit a response increased in control rats, a finding consistent with increased body 
mass occurring in this period (Table 1), and plateaued thereafter (Fig. 1A).  In VD- rats, mechanical 
sensitivity was normal through week 2 of the diet, but was increased by week 3 and was significantly 
higher than controls by week 4 (Fig 1A).  Rats receiving the vitamin D-deficient diet with elevated Ca 
showed normal sensitivity at week 1, but marked hypersensitivity by week 2 and thereafter (Fig. 1A).  
Thus, the high calcium diet not only failed to reverse the hyperalgesic phenotype; it accelerated the onset 
of deep tissue hypersensitivity.  These findings support the hypothesis that dietary vitamin D deficiency 
produces muscle hypersensitivity within 2-3 weeks in rats. 
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Gloth et. al first described patients with vitamin D deficiency attributed pain, which was triggered 
by minimal movement or touch (Gloth, Lindsay et al. 1991).  Accumulating evidence supports a causal 
role for vitamin D deficiency in some (Benson, Wilson et al. 2006; de Torrente de la Jara, Pecoud et al. 
2006; Glerup and Eriksen 1999; Gloth, Lindsay et al. 1991; Heidari, Shirvani et al. 2010; Macfarlane, 
Palmer et al. 2005; McBeth, Pye et al. 2010; Plotnikoff and Quigley 2003), but not all (e.g. fibromyalgia 
(Block 2004; de Rezende Pena, Grillo et al. 2010; Heidari, Shirvani et al. 2010; Tandeter, Grynbaum et 
al. 2009; Warner and Arnspiger 2008)) types of musculoskeletal pain.  However, it is unclear whether 
hypersensitivity is generalized.  To determine if hypersensitivity was apparent in other modalities, we 
evaluated cutaneous sensitivity of the hind paw plantar surface using a von Frey calibrated 4g 
monofilament.  The percentage of applied mechanical stimuli that elicited a withdrawal response was 
assessed on a weekly basis.  There were no differences between groups in cutaneous sensitivity at any 
week (Fig 1B).  Therefore, while a vitamin D deficiency resulted in deep tissue mechanical 
hypersensitivity, this does not appear to be due to wide-spread changes in sensory threshold that affect 
cutaneous mechanical withdrawal latencies. 
Changes in muscle sensitivity could affect other types of behavior, including balance and 
coordination.  Accordingly, vitamin D deficient rats were tested for normal balance in a beam-walk test.  
Rats were trained to walk along a 110cm long, 2.5cm diameter elevated beam to an enclosed platform.  At 
week 0, week 2, and week 4, this activity was video-recorded and analyzed to determine the number of 
times that their footfalls slipped off the beam.  Rats receiving a normal diet showed substantial 
improvement in traversing the beam between 0 and 2 weeks, and slips remained low at 4 weeks (Fig. 1C).  
Rats receiving the VD- diet, however, failed to show improvement at 2 weeks or 4 weeks.  Rats receiving 
the vitamin D deficient diet supplemented with Ca performed worse than either control or VD- groups at 
week 2 and failed to improve during the course of the study.  Because the vitamin D deficient rats, 
especially the VD-/+Ca rats, tended to sit lower on the beam, use more caution, and make more balance 
corrections, these data may underestimate the true extent of motor coordination deficits evoked by 
vitamin D deficiency.   
The balance deficits observed in vitamin D deficient rats could be secondary to alterations in 
sensory innervation, but may also be due to myopathic changes in muscle that occur with protracted 
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vitamin D deficiency (Schott and Wills 1976).  To assess any overt muscle dysfunction, we conducted 
grip strength analyses (Fig. 1D).  Forelimb grip strength increased with age in all groups, and vitamin D-
deficient rats showed no deficits relative to rats on normal diets, indicating an absence of gross muscle 
dysfunction.  To determine whether the apparent balance deficits were due to problems in mobility, the 
general locomotor activity of each rat was analyzed in a force-plate actimeter (BASi).  There were no 
significant differences in the overall locomotor activity between treatment groups, including total distance 
traveled (Fig.1E) and number of rearing events (Fig. 1F).  Thus the balance deficits do not appear to result 
from grossly limited locomotor mobility or overt muscle weakness.  
Because vitamin D deficiency and deep muscle hypersensitivity are well established by four 
weeks after the initiation of vitamin D deficient diets, we examined tissues at this time.  Calf muscle 
volume (Fig. 2A) and weight (not shown), were essentially identical in all groups, corroborating 
measurements of muscle strength and confirming an absence of measurable muscle atrophy in the vitamin 
D-deficient animals at this stage.  It has been argued that musculoskeletal pain in vitamin D deficiency is 
caused by the expansion of uncalcified bone matrix, resulting in pressure on the richly innervated 
periosteum (Mascarenhas and Mobarhan 2004).  Despite normal serum calcium, prolonged vitamin D 
deficiency in rats can result in shortened and bent tibia with enlarged and disorganized epiphyseal growth 
plates (Lester, VanderWiel et al. 1982).  However, in the current study, tibiae from the vitamin D-
deficient rats showed no overt abnormalities or differences in size or shape relative to controls.  
Histological analyses of decalcified tibial sections also showed organized growth plates with no 
expansion, either by height or number of chondrocytes per cartilage column (S3 and S4).  No changes in 
diaphysis circumference or marrow area were present (S4).  These findings comport with observations 
that muscle symptoms in vitamin D deficiency occur prior to bone pathology (Masood, Narang et al. 
1989), and suggest that gross changes in muscle or bone integrity do not underlie deep muscle pain in the 
early stages of vitamin D deficiency. 
There is growing evidence that many clinical pain syndromes are accompanied by nociceptor 
axon sprouting within affected peripheral tissues (Alfredson, Ohberg et al. 2003; Bohm-Starke, Hilliges et 
al. 1999; Schubert, Weidler et al. 2005).  Because steroid hormones other than vitamin D can influence 
sensory axonal outgrowth (Blacklock, Johnson et al. 2005), we examined innervation of control and 
61 
 
vitamin D deficient muscle.  Sections were immunostained for peripherin, a marker used to identify intact 
unmeylinated axons (Goldstein, House et al. 1991).  VD-/+Ca and VD- rats showed nearly a twofold 
increase in peripherin-immunoreactive (-ir) nerve density relative to controls (Fig. 2B, 3A-C).  To 
identify which populations of c-fibers are increased in vitamin D-deficiency,  sections of muscle were 
immunostained for calcitonin gene related peptide (CGRP) as a marker for ‘peptidergic nociceptors’ 
(Lawson 1992), and vesicular monoamine transporter 2 (VMAT2) as a marker for noradrenergic 
sympathetic axons (Headley, Suhan et al. 2007).  CGRP-ir axon density was increased approximately 
twofold (Fig. 2C, 3D-F) while that of VMAT2-ir was not significantly changed (Fig 2D and 3G-I).  To 
address whether the myelinated fibers innervating the muscle are affected by vitamin D deficiency, 
muscle  sections were immunostained for neurofilament H (NFH), a marker of large myelinated motor 
and proprioceptive fibers, and bungarotoxin, which reveals terminal muscle innervation by staining motor 
end plates.  We found no significant changes in sectional area of NFH-ir (Fig 2E and 3J-L) or 
bungarotoxin between control and vitamin D deficient muscles.  These findings indicate that vitamin D 
deficiency leads to selective muscle hyperinnervation by unmyelinated fibers, which are most likely 
peptidergic nociceptors. 
We recently reported that adult sensory dorsal root ganglion neurons contain vitamin D receptors 
and metabolic enzymes (Tague and Smith 2010).  Accordingly, vitamin D deficiency could affect muscle 
innervation through a direct action on DRG neurons.  To test this hypothesis, adult DRG neurons were 
grown in vitro.  The expression of VDRs by cultured neurons was first verified; results reveal VDR 
localized to the nucleus and somal cytoplasm (Fig. 4A, B).  Interestingly, VDR was concentrated within 
growth cones of peripherin-ir neurites, and co-localized with the growth associated protein GAP43 (Fig. 
4C-E), suggesting a role for VDR in growth cone kinetics.  
To determine if vitamin D levels influence unmyelinated sensory axonal architecture, DRG 
neurons were cultured with various concentrations of 1,25(OH)2D3.  The normal mean serum 
concentration of 1,25(OH)2D is approximately 80pM (Lund and Sorensen 1979), and patients with severe 
musculoskeletal pain are reported to have levels ranging from 12pM to 45pM (Gloth, Lindsay et al. 
1991).  To mimic this range, 1,25(OH)2D3 concentrations between 0 and 100pM were added to primary 
DRG cultures.  DRG neurons grown in concentrations of 1,25(OH)2D3 between 60pM and 100pM, 
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(corresponding to normal serum levels) showed typical axon outgrowth (Fig. 4F&I).  Below 60pM there 
was a steady increase in neurite outgrowth until 20pM, where outgrowth peaked at 60% greater than 
controls (Fig. 4G, I).  These findings indicate that 1,25(OH)2D3 can have direct effects on the outgrowth 
of sensory unmyelinated neurons.  At normal physiological levels it inhibits neurite outgrowth, and 
therefore correlates with the in vivo increases in muscle innervation during vitamin D deficiency. 
We assessed whether vitamin D deficiency promotes growth of other peripheral nerve axons by 
examining whether superior cervical ganglion (SCG) neurons are affected by 1,25(OH)2D3.  The 
expression of VDR in sympathetic neurons in vivo and in culture was first assessed.  Similar to small-
fiber DRG neurons, VDR-ir was present in both cytoplasmic and nuclear compartments of SCG neurons 
(S5 A&C).  However, while VDR was concentrated at the growth cone of sensory neurites, it appeared 
evenly distributed throughout sympathetic neurites, and was not enriched in the axon terminal (S5 C&E).  
SCG neurons were cultured with 0pM, 20pM, or 100pM 1,25(OH)2D3.  In contrast to small-diameter 
sensory neurons, 1,25(OH)2D3 had no effect on peripherin-ir neurite outgrowth from sympathetic neurons 
(S5 F).  This is consistent with in vivo findings demonstrating that VMAT2-ir axon density did not 
change in muscles of rats with vitamin D deficiency, and supports the hypothesis that vitamin D 
deficiency produces selective effects on c-fiber sensory neurons. 
The vitamin D-induced outgrowth of sensory but not sympathetic axons suggests that vitamin D 
signaling may differ between these two types of neurons.  VDRs can signal through either classical 
genomic or rapid response pathways via membrane-bound/cytoplasmic receptors that modulate ion flux 
and generation of second messengers (Mizwicki and Norman 2009).  The enrichment of VDR in growth 
cones of sensory but not sympathetic axons is consistent with the latter rapid signaling mechanism in 
regulating axonal outgrowth.  To determine if sensory axon outgrowth is regulated by rapid 
membrane/cytoplasmic signaling mechanisms, we used 6-s-cis lumisterol (JN), which selectively binds to 
and activates membrane VDRs but has no effect on nuclear VDR signaling (Norman, Okamura et al. 
1997).  JN was applied to DRG cultures in the same concentrations as 1,25(OH)2D3 in the previous 
experiment.  Immunostaining for large diameter NFH-ir neurons, which in vivo primarily express only 
nuclear VDRs (Tague and Smith 2010), showed no effect of JN on outgrowth, indicating that large 
diameter neurons fail to respond to membrane/cytoplasmic VDR activation with increased outgrowth 
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(Fig. 4J).  However, JN did elicit neurite outgrowth of peripherin-ir fibers at concentrations similar to 
those of 1,25(OH)2D3, with peak outgrowth also occurring around 20pM (Fig. 4J).  Therefore, VDR rapid 
response mechanisms likely regulate neurite outgrowth from sensory c-fiber neurons. 
Musculoskeletal pain affects up to 50% of adolescents and adults (Bergman 2007; De Inocencio 
2004) and is the second leading cause of lost productivity due to pain (Stewart, Ricci et al. 2003), making 
this an important clinical problem.  Vitamin D supplementation is reported to be a safe and effective 
approach for reversing this pain in some individuals (de Torrente de la Jara, Pecoud et al. 2006; Glerup 
and Eriksen 1999; Gloth, Lindsay et al. 1991; Heaney 2008). Our findings show that rats fed a vitamin D-
deficient diet also have deep muscle pain, providing evidence for a role of vitamin D in some muscle pain 
syndromes.   
Hypovitaminosis D-induced mechanical hypersensitivity was not secondary to, nor exacerbated 
by hypocalcemia in our model.  In fact, high dietary calcium concentrations appeared to accelerate 
vitamin D deficiency-induced increases in deep tissue sensitivity.  In vitamin D deficiency, hypocalcemia 
can lead to increased parathyroid hormone release, which increases CYP27B1 activity resulting in greater 
conversion of 25(OH)D to 1,25(OH)2D.  In fact, when serum 25(OH)D levels drop below 40nM, 
1,25(OH)2D levels often increase (Need, Horowitz et al. 2000).  However, this is not always the case, as 
all patients with pain in the study by Gloth et. al. had 1,25-dihydroxyvitamin D3 serum concentrations 
below 45pM (Gloth, Lindsay et al. 1991).  All of the patients tested in that study had normal serum 
calcium levels, and most were reportedly taking calcium supplements or multivitamins.  In rats, elevated 
dietary calcium inhibits CYP27B1 expression and attenuates the initial spike in serum 1,25(OH)2D, and 
accelerates its reduction (Anderson, Lee et al. 2010; Mallon, Boris et al. 1981), and may well account for 
the more rapid onset of muscle sensitivity in our rats receiving calcium-enriched chow.  In view of how 
common dietary calcium supplementation is, this may be a clinically important factor modulating muscle 
sensitivity in vitamin D-deficient patients.  
The finding that the affected tissue also shows selective hyperinnervation by putative nociceptors 
is in accord with reports in which hypersensitivity is accompanied by abnormal increases in numbers of 
presumptive pain-sensing nerves (Alfredson, Ohberg et al. 2003; Bohm-Starke, Hilliges et al. 1999; 
Schubert, Weidler et al. 2005).  While the contribution of increased innervation to pain sensitivity remains 
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unclear, actively growing axons show greater excitability than do quiescent axons (Janig, Grossmann et 
al. 2009), as do neurons with more complex axonal geometries (Janse, Peretz et al. 1999).  Similarly, 
more extensive axonal branching is likely to result in greater summation of locally evoked depolarizing 
potentials.  Accordingly, the finding that low vitamin D levels induce sensory c-fiber sprouting is 
consistent with the increased muscular sensitivity observed in vitamin D deficient rats.  Regarding 
locomotor activity and balance, the current observations are consistent with a clinical study, showing that 
while low vitamin D levels were associated with increased fall risk, they were  not associated with 
decreased grip strength or gait speed (Faulkner, Cauley et al. 2006).  Whether increased mechanical 
muscle sensitivity also contributes to the balance deficits and increased risk of falling in vitamin D-
deficient humans (Annweiler, Montero-Odasso et al. 2010) remains to be determined.   
Vitamin D metabolites are known to regulate nervous system development (Levenson and 
Figueiroa 2008), but a role in postnatal sensory axon growth has not been reported previously.  In this 
regard, vitamin D deficiency appears to be selective to c-fiber sensory neurons, as reduced 1,25(OH)2D3 
levels did not increase neurite growth by sympathetic neurons or large fiber sensory neurons.  
Hypovitaminosis D-induced sensory axon sprouting appears to involve signaling by 
membrane/cytoplasmic rapid response VDRs.  Rapid VDR signaling can affect intracellular calcium 
mobilization (Norman, Okamura et al. 1997), and growth cone calcium homeostasis is known to influence 
growth cone kinetics (Gomez and Zheng 2006).  Thus, VDR-mediated regulation of growth cone calcium 
channels represents a likely mechanism mediating sensory axon outgrowth.  While we are just beginning 
to explore the details of this phenomenon, the implications are exciting, as unlike many other pain 
therapies, proper vitamin D supplementation is safe, inexpensive, and has virtually no side-effects 
(Heaney 2008).  
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TABLES 
Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 Diet Food Intake Weight Serum 25D Serum Ca 
Serum 
P 
 Vitamin 
D3 
(IU/g) 
Ca 
(%) 
P 
(%) 
Week 2 
(kcal/day) 
Week 4 
kcal/day 
Week 
0  
(g) 
Week 
2  
(g) 
Week 
4  
(g) 
Week 2 
(nmol/L) 
Week 4 
(nmol/L) 
Week 4 
(mg/dL) 
Week 4 
(mg/dL) 
Control 2.2 0.47 0.3 58.9±0.4 63.7±0.1 164±4 224±5 264±5 51.8±6.0 70.8±6.3 11.0±0.1 8.5±0.4 
VD-/+ 
Ca - 2.5 1.5 64.1±1.3* 67.8±1.9* 168±4 225±6 262±9 24.6±5.5* 6.6±0.7* 11.0±0.1 8.3±0.4 
VD- - 0.47 0.3 59.9±0.3 66.4±0.6* 166±3 224±2 260±5 18.3±2.5* 4.2±1.5* 11.0±0.1 8.8±0.4 
 
*p<0.05 compared to control. Values shown are means±SE 
      
Table 1. Diet, weight, and serum analysis.   
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Table 2. 
 
 
 
 
 
 
 
 
 
 Growth Plate Diaphysis 
 Thickness (µm) 
Cell #/ 
column 
Circumference 
(mm) 
Marrow area 
(mm2) 
Control 282±20 20.8±0.9 6.9±0.1 3.5±0.1 
VD-/+Ca 274±25 20.0±1.0 7.1±0.4 3.6±0.3 
VD- 279±14 21.1±1.0 6.8±0.4 3.5±0.2 
 
 
Table 2. No changes in bone parameters were found in rats fed a vitamin D deficient diet for four weeks.   
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FIGURES 
Figure 1. 
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Figure 1. Experimental timeline. Experimental procedures are indicated on a timeline of rat age. 
. 
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Figure 2. 
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Figure 2. Modification of the digital Randall Selitto instrument (IITC Life Science Inc).  A plastic cap 
with a 0.5cm diameter surface area was placed over the pressure sensor. 
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Figure 3. 
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Figure 3 Behavioral comparisons of control (○), VD-/+Ca (■), and VD- (▼) rats. (A) Changes in deep 
tissue pressure sensitivity, measured as the maximum force (g) required to elicit an attempted limb 
withdrawal or vocalization to mechanical compression of the calf muscle. (B) There were no changes in 
cutaneous mechanical sensitivity as measured by the percentage of withdrawal responses to the 
application of a 4g monofilament to the plantar surface of the hind paw. (C) Changes in balance were 
measured by the number of hind paw slips while traversing an elevated 2.5cm diameter 110cm long 
beam.  VD- and VD-/+Ca rats failed to improve, while control rats improved compared to initial 
performance. (D) There were no changes in forelimb grip strength, as measured by the force (g) required 
to break the rats grip. (E-F) Assessment of locomotor activity during a five minute recording using a 
force-plate actimeter revelealed no changes in the (E) distance traveled or (F) number of rearing events. 
(*p<0.05 compared to control in same week, #p<0.05 compared to VD- in same week, ## p<0.5 
compared to week 0 within the same group). 
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Figure 4. 
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Figure 4. Representative images of  tibial growth plates from rats after four weeks on (A) control, (B) 
VD-/+Ca, or (C) VD- diets.  Sagittal sections (20µm) of the growth plate stained with hematoxylin and 
eosin. 
  
75 
 
 
Figure 5. 
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Figure 5. Comparisons of innervation densities of the lateral gastrocnemius muscles of rats after four 
weeks on control, VD-/+Ca, or VD- diets.  (A) There were no changes in the volumes of the calf muscles 
as measured by fluid displacement.  (A-E) There were significant increases in the percentage of nerve 
area per field area of (B) peripherin-immunoreactive (ir) (c-fibers) and (C) CGRP-ir (sensory 
peptidergic/nociceptor) nerves, but not (D) VMAT2-ir (sympathetic) or  (E) NFH-ir (large fiber) nerves.  
(F) There were also no changes in neuromuscular junction (NMJ) area as measured by bungarotoxin 
binding.    
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Figure 6. 
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Figure 6. Representative images of the immunoreactive nerves in calf muscle.  Transverse sections 
(20µm) of the lateral gastrocnemius of rats receiving (A,D,G,J) control, (B,E,H,K) VD-/+Ca, or 
(C,F,I,L) VD- diets were immunoflourescently-labeled for (A-C) peripherin (green), (D-F) CGRP (red), 
(G-I) VMAT2 (red), or (J-L) NFH (red) and Bungarotoxin (green). (Scale 50µM) 
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Figure 7. 
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Figure 7. 1,25(OH)2D3 acts directly on c-fiber sensory nerves to regulate axonal growth. (A-B) Primary 
DRG cultures immunoflourescently stained for (A) peripherin and (B) vitamin D receptors (VDR), 
showing VDR is expressed by cultured sensory neurons, and localized to both the nucleus and the 
cytoplasm (Scale 50µm).  (C-E)  At a higher magnification it is possible to see that (E) VDR is localized 
to the tip of (C) peripherin-ir neurites, along with the growth cone marker, (D) growth associated protein 
43 (GAP43) (Scale 5µm).  (F-H) Representative images of neurons treated with (F) 0, (G) 20, or (H) 
100pM 1,25(OH)2D3 (Scale 50µm).  (I) Fold change in peripherin-ir neurite area per neuron at the 
indicated 1,25(OH)2D3 concentrations.  Results reveal a biphasic curve with the peak at 20pM 
1,25(OH)2D3.  The shaded area corresponds to reported 1,25(OH)2D3 levels in patients with severe pain 
(Gloth, Lindsay et al. 1991). (J) DRG cultures treated with JN, a selective agonist for 
membrane/cytoplasm-localized rapid response VDRs, and stained for peripherin (●) or NFH (□).  While 
there was no significant change in NFH-ir neurite area /neuron, there was a biphasic response to JN, with 
a peak at 20pM. (*p<0.05)   
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Figure 8. Sympathetic neurons express VDRs, but 1,25(OH)2D3 has no effect on neurite outgrowth.  (A) 
Sympathetic neurons of superior cervical ganglia (SCG) were immunoflourescently labeled for VDR.  
VDR was localized to the nucleus and cytoplasm of selected neurons.  (B-E)  Primary SCG cultures 
immunoflourescently-stained for (B&D) peripherin and (C&E) VDR (Scale B&C 50µm, D&E 5µm).  
VDR was localized throughout the (C) cell body, (E) neurite, and growth cone. (F) Primary SCG cultures 
were grown for 48 hours with 0pM, 20pM, or 100pM 1,25(OH)2D3 and immunoflourescently labeled 
with peripherin.  There were no significant changes in neurite area/neuron.  
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CHAPTER 4. GENERAL CONCLUSIONS AND DISCUSSION 
  
84 
 
 
While the evidence linking vitamin D deficiency and musculoskeletal pain has been 
accumulating, these are the first studies to show a direct causal relationship.  In the rat model described 
here, vitamin D deficiency leads to deep tissue hypersensitivity, which occurred concurrently with muscle 
hyperinnervation by putative nociceptors.  This hyperinnervation likely contributes to hypovitaminosis D-
induced musculoskeletal pain and neither hypersensitivity nor hyperinnervation is related to serum 
calcium levels.   
 These are also the first studies to show direct actions of vitamin D metabolites on sensory 
neurons. Both vitamin D receptors and metabolic enzymes are found in c-fiber neurons, indicating the 
importance of tightly regulating vitamin D signaling in this cell population. At normal physiological 
concentrations, 1,25(OH)2D3 appears to directly act on membrane/cytoplasmic rapid response vitamin D 
receptors, possibly within the growth cone, to inhibit axonal sprouting from c-fiber sensory neurons.  A 
vitamin D deficiency therefore reduces this inhibition, resulting in tissue hyperinnervation. These effects 
are cell-type specific, as hypovitaminosis D-induced axonal growth is not apparent with large fiber 
sensory neurons or sympathetic neurons either in vivo or in culture. Expression of both the ligand and 
cytoplasmic VDR is modulated by ovarian hormones, with the overall effect of reducing vitamin D 
signaling when ovarian hormones are suppressed.  This in itself could lead to tissue hyperinnervation and 
hypersensitivity or perhaps exacerbate the effects of a vitamin D deficiency, accounting for the increased 
incidence of musculoskeletal pain in women with suppressed ovarian hormones. 
 
Musculoskeletal Pain Management 
With an estimated 27.5-36% of adolescents and 30-50% of adults suffering from chronic 
musculoskeletal pain (Bergman 2007; De Inocencio 2004), our current pain prevention and pain 
management strategies are clearly not effective.  The most common drug therapies for chronic pain are 
NSAIDS (44%), weak opioids (i.e. tramadol, codeine) (23%), and acetaminophen (18%) (Breivik, Collett 
et al. 2006), all of which can have significant safety concerns.  For example, 20% of patients taking 
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NSAIDS longer than two months will develop an ulcer and 1:1200 will die from gastroduodenal 
complications (Tramer, Moore et al. 2000); patients taking tramadol are at increasesd risk for developing 
seizures and life threatening serotonin syndrome (Sansone and Sansone 2009); and acetaminophen is 
reported to cause acute liver and renal failure if not taken properly (Graham, Scott et al. 2005).  In 
addition to the potential side effects, in many cases these drugs are not efficient in managing pain.  In fact 
only 36% of chronic pain patients report that their current therapies are adequate for managing pain 
(Breivik, Collett et al. 2006).  Non-pharmacological pain management strategies on the other hand often 
have limited or short term effects.  Massage, manipulation, or mobilization therapies may have short-term 
benefits, but there is no evidence that they have a positive long-term impact on chronic musculoskeletal 
pain (Airaksinen, Brox et al. 2006).  There is also no evidence that hyperstimulation analgesia (i.e. 
acupuncture or transcutaneous electrical nerve stimulation) or relaxation techniques have lasting effects in 
studies analyzing chronic lower back pain (Airaksinen, Brox et al. 2006; Carroll and Seers 1998).  
Cognitive behavioral therapies, designed to change how patients perceive and react to their pain, have had 
positive results, but outcomes may be highly dependent on the social and physcological variables of the 
patient (McCracken and Turk 2002).  Regular exercise may also help treat and prevent chronic pain, but 
patient adherence is low (Jordan, Holden et al. 2010).   It therefore appears that neither current 
pharmacological nor alternative therapies for managing chronic musculoskeletal pain are sufficient. 
This study is novel because it indicates that maintaining a healthy vitamin D status could prevent 
the development of some forms of muscle pain.  The number of people suffering from hypovitaminosis 
D-induced musculoskeletal pain may be substantial, as up to 93% of patients with non-specific 
musculoskeletal pain are vitamin D deficient (Plotnikoff and Quigley 2003).  While the model described 
here does not show whether vitamin D supplementation can reverse musculoskeletal pain once 
established, a number of clinical studies suggest that it can (de Torrente de la Jara, Pecoud et al. 2006; 
Glerup and Eriksen 1999; Gloth, Lindsay et al. 1991).  Proper vitamin D supplementation may therefore 
be a relatively easy, inexpensive, and safe way to treat and prevent non-specific musculoskeletal pain.   
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Tissue Hyperinnervation and increased sensitivity 
Nociceptor hyperinnervation could increase peripheral input of pain signals to the spinal dorsal horn 
in a number of ways.  It is known that actively growing axons show greater excitability than do quiescent 
axons (Janig, Grossmann et al. 2009).  Neurons with more complex axonal geometries also show greater 
excitability (Janse, Peretz et al. 1999), perhaps because of greater spatial summation on the nociceptor 
itself.  Similarly, more extensive axonal branching is likely to increase the number of nociceptors 
activated, resulting in greater spatial summation on postsynaptic terminals.  It is also known that 
nociceptors can couple in the periphery (Meyer, Raja et al. 1985).  In other words, the action potential of 
one neuron can initiate an action potential in adjacent neurons. If innervation density is increased, each 
neuron may come in contact with a larger population of neurons with which to couple, which could 
further increase the number of nociceptors activated per stimulus. Through any or all of these 
mechanisms, increased neurite outgrowth may enhance nociception.  
 
Transition to Chronic Pain 
 Results from this study indicate that vitamin D deficiency causes peptidergic nociceptor 
hyperinnervation of the muscle, which could lower the nociceptive threshold and account for the observed 
deep tissue mechanical hypersensitivity.  However, this hyperinnervation also has the potential to lead to 
chronic (unevoked) pain.  In addition to their afferent actions, the peptidergic c-fibers, can antidromically 
release neuropeptides that promote neurogenic inflammation (Maggi 1995; Richardson and Vasko 2002).  
Once activated, the nerve endings release CGRP and tachykinins, which cause vasodilation, protein 
extravasation, mast cell degranulation, and infiltration and activation of immune cells, leading to tissue 
inflammation (Maggi 1995).  This comes full circle, as deep tissue inflammation in turn further increases 
the production of CGRP and tachykinins (Ambalavanar, Moritani et al. 2006) and results in the release of 
cytokines, growth factors and other substances from the tissue, which sensitize nociceptors (Richardson 
and Vasko 2002).  If peptidergic c-fibers are found at a high density in vitamin D deficient patients, 
neurogenic inflammation could be amplified as there are more nerve endings to release pro-inflammatory 
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substances.  CGRP content itself may also be higher in the neurons of vitamin D deficient patients. 
1,25(OH)2D is a well-established repressor of cAMP-induced CT/CGRP gene transcription and an 
inhibitor of CT and CGRP secretion from thyroid C-cells, thus with the removal of this repression, the 
loss of vitamin D may enhance CGRP expression and secretion and promote neurogenic inflammation 
(Baier, Grauer et al. 1994; Collignon, Laborie et al. 1992; Cote, Rogers et al. 1987; Lamari, Tahri et al. 
1994; Lazaretti-Castro, Grauer et al. 1995; Lazaretti-Castro, Grauer et al. 1990; Naveh-Many, Raue et al. 
1992; Naveh-Many and Silver 1988; Raue, Deutschle et al. 1984; Raue, Deutschle et al. 1983).  
Furthermore, vitamin D deficient patients may be particularly susceptible to inflammation, as vitamin D 
metabolites act as inflammatory inhibitors (Baeke, Gysemans et al. 2010).  Once sensitized by 
inflammation, the nociceptors may spontaneously discharge (Xiao and Bennett 2008).  Prolonged firing 
of nociceptors, this can cause glutamate release in the spinal cord, which acts on NMDA receptors, 
leading to central sensitization (Bennett 2000).  In addition, if CGRP levels are elevated in peptidergic 
nociceptors due to vitamin D deficiency, central sensitization may be further enhanced, as the central 
release of CGRP has been shown to potentiate the response of NMDA and non-NMDA receptors in the 
spinal dorsal horn, facilitating wind-up (Leem, Gwak et al. 2001). It is therefore possible that vitamin D 
deficient patients may transition from a state of deep tissue hypersensitivity to a chronic pain state 
through inflammation and central sensitization.  At this point it is unclear whether vitamin D deficiency 
may play a role in establishing or maintaining central sensitization within the brain, but this possibility 
cannot be ruled out, as VDR is expressed in both neurons and glia throughout the brain (Baas, Prufer et al. 
2000; Eyles, Smith et al. 2005; Glaser, Veenstra et al. 1999; Neveu, Naveilhan et al. 1994; Perez-
Fernandez, Alonso et al. 1997; Prufer, Veenstra et al. 1999; Walbert, Jirikowski et al. 2001).   
 
Gender differences and the role of sex hormones 
Although both musculoskeletal pain and vitamin D deficiency are more common in women, 
vitamin D deficiency is also associated with musculoskeletal pain in men.  Results from the European 
Male Ageing Study analyzing 3075 men ages 49-79, found that 8.6% of all men had chronic widespread 
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pain.  25.5% of men with chronic widespread pain had 25(OH)D levels below 15ng/ml (37.5nmol/L), 
compared to only 18.6% in men with no pain (McBeth, Pye et al. 2010), suggesting that vitamin D 
deficiency may cause musculoskeletal pain in men.  However, chronic musculoskeletal pain in general is 
two times more prevalent in women than men (Bergman 2007).  It seems to be associated with reduced 
ovarian hormones, as musculoskeletal pain is a common menopausal symptom and a major side-effect for 
estrogen lowering drugs (i.e. aromatase inhibitors, GnRH agonists) (Alexander, Dennerstein et al. 2007; 
Gaugris, Heaney et al. 2005; Khan, Reddy et al. 2010).  This could simply be due to the increased 
incidence of vitamin D deficiency within this population; however, this study indicates that altered 
vitamin D signaling pathways within the nociceptors themselves may play a role.  Sustained suppression 
of ovarian hormones results in suppression of both local ligand and receptor concentrations within 
peptidergic neurons, which might decrease vitamin D signaling and exacerbate the effects of a vitamin D 
deficiency. The clinical study by Plotnikoff and Quigley (Plotnikoff and Quigley 2003) supports this 
hypothesis. They examined 150 patients who sought clinical treatment for non-specific musculoskeletal 
pain.  Reflecting the increased incidence of musculoskeletal pain in women, the study was comprised of 
107 women and 43 men. Most of the women were over the age of 50 and therefore likely to be post-
menopause. Almost all of the patients were vitamin D deficient (93%), but interestingly the women over 
the age of 50 had serum 25(OH)D levels that were significantly higher than either the women of 
childbearing age (<36 years old) or the men. Given our findings, this data may suggest that suppression of 
ovarian hormones in these postmenopausal women leads to reduced vitamin D signaling, causing 
musculoskeletal pain at earlier stages of a vitamin D deficiency. The reduced vitamin D signaling in 
putative nociceptors after hormone suppression may provide insight into another clinical situation.  
Patients taking aromatase inhihitors tend to be vitamin D deficient and have musculoskeletal pain (Khan, 
Reddy et al. 2010; Waltman, Ott et al. 2009). While vitamin D supplementation has been shown to be 
effective at reducing musculoskeletal pain in most vitamin D deficient patients, vitamin D 
supplementation only minimally reduced musculoskeletal pain in patients taking aromatase inhibitors, 
despite the fact that the supplementation increased serum levels of 25(OH)D (Khan, Reddy et al. 2010).  
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It is possible that aromatase inhibitor-induced hypoestrogenemia might severely hinder conversion of the 
therapeutic supplement to the active hormone, 1,25(OH)2D, and thereby limit receptor-mediated 
signaling, rendering dietary supplementation less effective. 
  
When vitamin D supplementation is not sufficient 
The good news is that many people with musculoskeletal pain may find relief with vitamin D 
supplementation, which when done correctly has no side effects (Heaney 2008).  In fact, a number of 
studies have shown this to be the case (de Torrente de la Jara, Pecoud et al. 2006; Glerup and Eriksen 
1999; Gloth, Lindsay et al. 1991).  However, understanding the mechanism may prove important for 
some populations who may not improve with simple vitamin D supplementation.  Patients taking estrogen 
lowering drugs as described above may be one population. In addition, patients on dialysis, who have a 
compromised ability to convert 25(OH)D to 1,25(OH)2D and who often suffer from musculoskeletal pain 
(Golan, Haggiag et al. 2009), may not benefit from vitamin D supplementation either, because they 
cannot produce adequate levels of active ligand.  One option is Vitamin D receptor activators (i.e. 
calcitriol); however, these carry a higher risk than traditional vitamin D supplements, because of their 
ability to promote hypercalcemia.  Alternatively, based on our findings that vitamin D deficiency causes 
an increase in the density of petidergic c-fibers within the muscle, it is possible that therapies that 
desensitize these peripheral nerve endings (i.e. TRPV1 antagonists) may prove beneficial for 
musculoskeletal pain.     
Dietary calcium and hypovitaminosis D-induced musculoskeletal pain 
Some of the effects of a vitamin D deficiency are not due to the direct actions of this hormone, 
but rather due to secondary hypocalcemia (i.e. reduced fertility and increased vascular muscle 
contractility) (Johnson and DeLuca 2002; Uhland, Kwiecinski et al. 1992; Weishaar and Simpson 1987).  
However, it appears that hypovitaminosis D-induced muscle pain is not due to secondary hypocalcemia.  
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In fact, the results from this study suggest that high dietary calcium concentrations in vitamin D 
deficiency may actually exacerbate this condition.  It is interesting to note that all patients with severe 
pain in the study by Gloth et. al. had low 1,25(OH)2D serum concentrations, normal serum calcium 
concentrations, and most were taking a calcium supplement (Gloth, Lindsay et al. 1991).  Dietary calcium 
concentrations are important to consider, because they may affect 1,25(OH)2D concentrations. 
1,25(OH)2D does not always decrease in a vitamin D deficiency, and in fact when serum 25D levels drop 
below 40nM, 1,25(OH)2D levels often increase (Need, Horowitz et al. 2000).  This is because as serum 
Ca concentrations drop in a vitamin D deficiency, parathyroid hormone levels increase, which increases 
expression of CYP27B1, the enzyme responsible for converting 25(OH)D to 1,25(OH)2D.  It is possible 
that high dietary calcium may prevent the drop in serum calcium that leads to increased PTH levels, 
thereby preventing a spike in 1,25(OH)2D levels.  This appears to be the case in rats, because increased 
dietary calcium inhibits expression of CYP27B1, abrogates the 1,25(OH)2D spike, and accelerates the 
decrease of 1,25(OH)2D in a vitamin D deficiency (Anderson, Lee et al. 2010; Mallon, Boris et al. 1981). 
If high dietary calcium reduces the levels of active hormone, this could be the reason why increasing 
dietary calcium accelerated the onset of deep tissue hypersensitivity in this study.  In view of how 
common dietary calcium supplementation is (43% of population use Ca supplements) (Bailey, Dodd et al. 
2010), it may be an import aspect for a doctor to consider when suspecting hypovitaminosis D-induced 
musculoskeletal pain.  
Beyond Pain 
 It is unlikely that nociceceptor-sprouting in response to vitamin D deficiency evolved for the sole 
purpose of causing pain, so it is interesting to consider the evolutionary benefits of this process. One 
potential benefit could be increased regulation of blood flow to skeletal muscle.  Vitamin D deficiency is 
already known to have profound effects on the cardiovascular system.  As vitamin D levels drop, blood 
pressure rises (Scragg, Sowers et al. 2007). This alone could increase tissue blood flow in vitamin D 
deficiency.  This may be important for individuals living at higher latitudes, who experience dramatic 
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seasonal variations in temperature, have low serum 25(OH)D during the winter months (Holick 2005), 
and are known to have elevated blood pressures in the winter (Woodhouse, Khaw et al. 1993).  If this 
drop in vitamin D levels results in increased blood flow to peripheral tissues, it could be important for 
maintaining heat in the extremities during cold winters.  In addition, the increased c-fiber innervation of 
skeletal muscle could also promote thermogenesis. Shivering thermogenesis is important for maintaining 
basal body temperatures in cold environments and involves the involuntary, rhythmic contractions of 
skeletal muscles.  Shivering requires a dramatic increase in oxygen consumption (~5 times the resting 
metabolic rate). An increase in peptidergic c-fibers in skeletal muscle, could locally increase oxygen 
delivery, by priming the blood vessels in the muscle for vasodilation. Upon activation of these nerves, 
peptidergic nociceptors antidromically release CGRP, which promotes vasodilation.  For example, 
electrical stimulation of the saphenous nerve results in muscle arteriolar dilation and increased blood flow 
to the gracilis muscle, which can be prevented by the CGRP receptor antagonist, CGRP8-37 (Loaiza, 
Yamaguchi et al. 2002).  The hypovitaminosis D-induced increases in the innervation of muscle by 
CGRP-containing nerves may therefore play a role in further increasing blood flow to the skeletal muscle, 
providing thermogenic advantages in colder climates.  In fact, it is known that individuals from higher 
latitude cold weather climates (e.g. Alaskans), who are known to have lower vitamin D levels (Holick 
2005) in the winter, are able to maintain higher temperatures in their extremities when exposed to cold 
than individuals from warmer climates, making them less susceptible to frost-bite (Miller and Irving 
1962).   
Potential Mechanisms 
 The results from this study indicate that 1,25(OH)2D3 is capable of acting directly on sensory c-
fibers to regulate neurite outgrowth.  1,25(OH)2D3  likely acts through membrane/cytoplasmic VDRs, 
which typically initiate rapid response signaling cascades.  The rapid response specific agonist, JN, has  
similar dose dependent effects on neurite growth as 1,25(OH)2D3. These rapid response cascades could 
be initiated locally within the growth cone, as VDR appears to be enriched there. (Mizwicki and Norman 
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2009).  The rapid responses known to be mediated by 1,25(OH)2D are likely cell type specific, but  
include PKC, MAPK, PLC, PLA2, Src, and Raf activation, opening Ca2+ and Cl- channels, and 
sphingomyelin hydrolysis (Mizwicki and Norman 2009). Any or all of these downstream signals could 
play a role in neurite outgrowth. One of the best characterized VDR rapid responses is regulation of the 
flux of ions such as calcium.  Like VDR activation,  calcium modulation has a biphasic curve on neurite 
outgrowth (Gomez and Zheng 2006).  In other cell types, membrane VDR regulates intracellular calcium 
concentrations through modulation of L-type calcium channels (Zanello and Norman 2004).  This is 
interesting, because L-type voltage gated channels are the primary source for inward calcium flux in c-
fiber neurons (Scroggs and Fox 1992) and they are known regulators of sensory neurite outgrowth 
(Archer, Doherty et al. 1999).  Therefore, while serum calcium concentrations were not a factor in the 
development of muscle pain, 1,25(OH)2D may regulate intracellular calcium concentrations within the 
axon.    
Conclusion 
Collectively, these results show that vitamin D deficiency does cause deep tissue hypersensitivity 
in rats. 1,25(OH)2D3 acts directly on membrane/cytoplasmic rapid response VDRs to regulate axonal 
growth from a sensory subtype considered to be nociceptive.  During a vitamin D deficiency, the reduced 
signaling from these rapid response VDR receptors leads to sensory hyperinnervation of muscle, which 
may contribute to the development of deep tissue hypersensitivity in rats. Suppression of ovarian 
hormones may further promote hypovitaminosis D-induced musculoskeletal pain by reducing vitamin D 
signaling within nociceptors.  This may contribute to the high prevalence of musculoskeletal pain in 
women with low levels of ovarian hormones.  Preventing the development of non-specific 
musculoskeletal pain may be as simple as supplementing the diet with vitamin D. 
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